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Abstract
Developmental exposure to bisphenol A (BPA), a ubiquitous endocrine disrupting
chemical, is associated with organ dysfunction and diseases in adulthood. However, little
is known about its effects on the adrenal glands. Therefore, this thesis addresses this
important question using both in vivo and in vitro approaches. BPA at environmentally
relevant doses was administrated via diet to pregnant mice from embryonic day 7.5 to
birth, following which mice were switched to a standard chow. At two months
postnatally, adrenal glands and blood samples were collected from adult mouse offspring
for structural and functional analysis. I found that: (a) BPA increased adrenal gland
weight as well as plasma corticosterone levels; (b) BPA did not alter plasma levels of
ACTH; and (c) BPA stimulated expression of the two key steroidogenic factors,
steroidogenic acute regulatory protein (StAR) and cyp11A1 in female but not male
offspring. To determine the molecular mechanisms underlying the BPA-induced StAR
expression, I used human fetal adrenal cortical H295A cells as an in vitro model system,
and showed that BPA increased StAR protein expression likely through an estrogen
receptor (ER)-mediated mechanism independent of StAR gene transcription, translation
and protein half-life. I then investigated the molecular mechanisms underlying the BPAinduced increase in adrenal gland weight using the same in vitro model system. I
demonstrated that (a) BPA increased cell number and protein levels of the three universal
markers of proliferation (proliferating cell nuclear antigen (PCNA), cyclin D1 and D2, as
well as sonic hedgehog (shh) and its key transcriptional regulator Gli1; (b) cyclopamine,
a shh pathway inhibitor, blocked these stimulatory effects of BPA on cell proliferation;
(c) BPA increased the nuclear translocation of ERβ; and (d) the ERb-specific agonist
DPN mimicked while the ERb antagonist PHTPP abrogated the stimulatory effects of
BPA on cell proliferation, and prevented BPA-induced activation of the shh signaling.
Taken together, these findings demonstrate that developmental exposure to BPA
adversely affects adrenal gland development and steroidogenic function in adult mouse
offspring. Furthermore, they reveal novel molecular signaling mechanisms of BPA
actions in regulating adrenal steroidogenic function and adrenal cortical cell proliferation.
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1

INTRODUCTION

2

1.1

Bisphenol A

Bisphenol A (BPA) is a widely used endocrine disrupting chemical (EDC) that has
become a source of major health concerns 1-3. With an estimated production of six billion
tons per year, BPA ranks as one of the most highly produced chemicals 4. Initially, it was
synthesized by Dr. A.P. Dianin in 1891 for use as a synthetic estrogen, however, the
discovery of more potent estrogenic compounds resulted in its discontinuation 2. During
the 1940s and 50s, BPA was identified as a potentially important component of plastics
and began to be utilized in the manufacture of polymers, polyvinyl chloride plastics, and
flame retardant tetrabromobisphenol-A

1-4

. Currently, it is commonly found in

polycarbonate plastics, such as plastic containers, baby bottles, plastic water bottles, etc.;
and in epoxy resins, which are used as an internal coating on food and beverage cans 5.
Additionally, BPA is present in medical and dental equipment, thermal paper, and
cardboard and has been detected in soil, water and air samples

2-4,6-8

. The BPA used in

packaging contains an ester bond linking BPA monomers onto polymers, making it
susceptible to hydrolysis, thus allowing migration of BPA from the packaging into the
contents 8. BPA has been demonstrated to leach out of plastic containers and liners of
cans into the food or beverage products, a process that is enhanced in acidic or high
temperature environments 2-4,6-8. The most common route of exposure to BPA is through
ingestion, but exposure through dermal routes and inhalation is also possible 5. BPA is
ubiquitous in the environment and is detectable in the urine of 91% of Canadians 9.
Several human epidemiological studies have demonstrated an association between
exposure to BPA and adverse health outcomes that include infertility, reproductive
complications, childhood obesity, childhood asthma, and altered neurological
development in children and adults

10-12

. Furthermore, animal studies have shown that

developmental exposure to BPA results in a wide range of adverse health effects
including reproductive, cardiovascular, immunological, metabolic, behavioral, and
neurological disorders, as well as certain cancers in adult offspring, and that many of
these effects are sex specific 2,6,13.

3

1.1.1

Mechanism of Action

BPA is considered an environmental estrogen and an EDC 2-4,6,7 with the ability to bind to
both α and β estrogen receptor subtypes (ER), androgen receptors (AR), G-protein
coupled estrogen receptors (GPER), estrogen related receptors γ (ERRγ) and
glucocorticoid receptors (GR)

5,7

. Recent evidence also indicates that BPA exposure

results in adverse effects through pregnane X receptors
activated receptors 15, thyroid hormone signaling
17

5,7,15

14

, peroxisome proliferator-

, NF-kB signaling 16, ion signaling

, and induces pro-inflammatory cytokines and chemokines

18,19

. Additionally, prenatal

BPA exposure, even at low doses, has been shown to cause epigenetic alterations,
including DNA methylation and histone modifications

20

. BPA’s effects on these

receptors and pathways are based on (1) the presence of the receptors, (2) the level of
expression of these receptors, (3) the dose of BPA, and (4) the level of endogenous
hormones that compete with BPA for binding to these receptors.

1.1.1.1

Estrogen Receptor

Of particular interest are the actions of BPA through the ERs, due to the structural
similarities of BPA to estrogen and its previous use as a synthetic estrogen (Figure 1.1)
15

. There are two distinct ER subtypes, ERα and ERβ, which are specific to cell type, with

ERα primarily expressed in reproductive and insulin-sensitive tissues

15

. Upon estrogen

binding to the ER, a conformational change occurs and ER translocates to the nucleus of
the cell. In the nucleus, ER can either bind (1) directly to estrogen response elements
(ERE) on promoters of ER target genes to induce gene expression or (2) to transcriptional
coactivators, such as Sp1 and Ap1 to induce gene expression 15,21.

4

Figure 1.1: Chemical structure of BPA and estradiol.2

5

BPA acts as an agonist for ERβ and has dual agonist or antagonist actions for ERα and
has a higher binding affinity to ERβ than to ERα 22-24. Thus, the effects of BPA on ER are
largely dependent on the cell type and ER subtype present 2. However, BPA has been
classified as a weak estrogen based on its low binding affinity for ER compared to
naturally-occurring 17β-estradiol (~10,000-fold lower) 2. This leads to the claim that
BPA will not have a large impact on ER in the presence of endogenous estrogens.
However, additive effects of BPA and estradiol together have been demonstrated

25

.

Additionally, the effects of BPA may be explained by the “spare receptor” hypothesis,
which states how a maximal response may be achieved by low concentrations of a
hormone (or EDC), before occupancy of receptors are saturated 22. In addition, BPA has
been shown to have non-genomic actions that are distinct from its actions on classical
ERs

22,26

. ER localized to the plasma membrane is known to activate a variety of

pathways depending on receptor and cell type, including the extracellular regulated
kinase/mitogen-activated protein kinase (ERK/MAPK), p38/MAPK, and phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathways

15

. Moreover, BPA has been

demonstrated to activate these non-genomic pathways by acting through membrane ER
15

.

1.1.1.2

GPER

GPER (also known as GPR30) is a G-protein coupled intracellular membrane receptor
that is activated by estrogen and responsible for rapid estrogen signaling

27

. BPA has

been shown to be a strong agonist of the GPER, having non-genomic effects similar to
estrogen

5,28

. BPA has a half maximal inhibitory concentration (IC50) of 630 nM for the

GPER, which is 8-50× higher than for classic ERs

28

. Additionally, BPA can displace

over 50% of the [3H] E2 binding to the plasma membrane of cells transfected with GPER,
demonstrating BPA’s ability to interfere with estrogen signaling 28.

1.1.1.3

Androgen Receptor

Since BPA also affects the male reproductive system, the results of BPA binding to the
androgen receptor have been investigated. BPA acts as a moderate antagonist of the AR
in numerous cell types

5,7,29,30

. BPA has an inhibitory concentration (IC50) value of

3.9×104 nM for the AR in MA-10 cells

29

. Additonally, BPA has been shown to

6

competitively bind to the AR and reduce AR nuclear translocation, and therefore its
activity 30.

1.1.1.4

Estrogen Related Receptor γ

ERRγ are a subfamily of orphan receptors similar to ERs that can bind to estrogen related
response elements as well as EREs 15. BPA has been shown to be a potent ERRγ agonist
5

, with an IC50 value of 13.1 nM, similar to that of the well-known strong ERRγ agonist

4-hydroxytamoxifen
ERRγ binding

15

31

. Thus, BPA may adversely affect signaling pathways through

. Moreover, there is potential for interaction or interference between

ERRs and ERs during both the developmental period and adulthood 15.

1.1.1.5

Glucocorticoid Receptor

Since BPA has been demonstrated to act as both a GR agonist and antagonist 5,29,32,33, the
actions of BPA on the GR may be tissue and dose specific. The affinity of BPA to the GR
is relatively low, with an IC50 value of 6.7×104 nM in MA-10 cells and has antagonistic
activity toward the GR

29

. In the adipose cell line 3T3-L1, BPA displayed agonistic

activity through the GR, which was also demonstrated in an in silico study

32,33

.

Additional evidence from our lab has demonstrated that BPA interferes with the
glucocorticoid signaling pathway, resulting in inhibition of glucocorticoid target genes in
A549 lung cells 16.

1.1.1.6

Epigentic Modifications

Recent evidence has emerged, supporting a potential for environmental chemicals to alter
the epigenome during the period of embryogenesis. BPA has been demonstrated to
induce numerous epigenetic alterations in rodent studies, including DNA methylation and
histone modifications

5,34,35

. For example, DNA methylation alterations have been

observed to result in a shift in coat color after prenatal BPA exposure in viable yellow
agouti mice 34. Moreover, oocyte maturation in porcine subjects was disrupted by BPA as
a result of DNA methylation and histone modifications 35.

1.1.2

Dose Response and Low Dose Effects

Regulatory agencies typically establish the lowest observable adverse effect level
(LOAEL) and/or no observed adverse effect level (NOAEL) for chemicals such as BPA

7
36

. This enables the calculation of a reference dose that is considered safe for human

exposure, based on the theory that “the dose makes the poison,” which stipulates that
high doses of a chemical result in a larger physiological effect or in an increase in
potential adverse effects

36

. This theory is challenged by the testing of EDCs

36

. In

contrast to traditional monotonic response curves, many EDCs including BPA, have nonmonotonic dose response curves (NMDRCs). Traditional monotonic response curves can
be either linear or non-linear, but the slope of the curve always remains in the same
direction

36

. NMDRCs are U-shaped or inverted U-shaped, such that the direction or

slope of the curve changes over the range of doses being examined 36. Thus, outcomes of
low-dose exposure to BPA cannot be inferred from results of higher dose exposures

37

,

making the traditional development method of LOAEL and NOAEL for BPA
problematic. Since all doses of BPA tested had adverse effects, negating the possibility of
determining a NOAEL value, the reference dose for human exposure of BPA was
calculated using the LOAEL

36

. Thus, the widespread use of BPA and consequent

ubiquitous exposure to BPA even at very low doses is of concern.

1.1.3

Pharmacokinetics

The metabolism of BPA in humans, rodents, and primates is similar and is thought to
occur through comparable mechanisms 38. Pharmacokinetic studies of BPA indicate that
large amounts of BPA are subject to first pass metabolism in the liver, where it is
conjugated into either the main metabolite, BPA-glucuronide (BPA-G), by uridine 5ʹdiphospho-glucuronosyltransferase (UGT) or BPA-sulfate (BPA-S) by sulfotransferase
(SULT). Among UGTs, UGT2B15 shows the highest activity for conjugating BPA into
BPA-G in human liver microsomes 39. In both rodents and humans, glucuronidation and
sulfation produce inactive hydrophilic BPA metabolites that is excreted in the feces

38,40

.

However, unconjugated BPA is cleared by the kidneys and eliminated in the urine of
primates, but is excreted primarily in the feces of rodents

38

. This difference in route of

elimination raises the question of potential differences in metabolism and circulating
levels of BPA. Taylor, et al.

38

demonstrated that oral administration of BPA results in

similar levels of unconjugated BPA in the circulation and identical rates of clearance in
non-human primates and rodents. However, in pregnant rhesus monkeys, the systemic
bioavailability or the percent of unconjugated BPA that reaches the systemic circulation

8

of BPA is considerably lower; only 0.48%

41

. Rapid conjugation of BPA was

demonstrated when pregnant rhesus monkeys were injected with 100 µg/kg bodyweight
(bw) of unconjugated BPA, and at the five-minute initial sampling point, 87% of the BPA
detected was in the conjugated form. The presence of unconjugated BPA in the blood
demonstrates either (1) incomplete first pass metabolism, (2) a bypass of first pass
metabolism or (3) the potential for deconjugation of BPA metabolites into unconjugated
BPA 4. Indeed, evidence suggests that in the intestine and colon, conjugated BPA can be
deconjugated back into active BPA in rodents 4. Clearly, additional investigation is
required to determine the pharmacokinetics of BPA and the potential differences in
experimental animal models versus human exposure to comprehend the risks of BPA
exposure.
During pregnancy, the placenta plays a critical role in controlling potential toxins that can
reach the fetal circulation (Figure 1.2). Detectable levels of BPA were present in the
placentae of rhesus monkeys given a single injection of 100 µg/kg bw BPA 41 and of that,
29% was unconjugated BPA

41

. Using a placental transfer model, 27% of unconjugated

BPA was shown to cross from the maternal circulation of the placenta to the fetal
circulation, indicating that unconjugated BPA can freely cross the placenta 42. Moreover,
this model demonstrated that the placenta plays no role in conjugating active BPA into
BPA-G, since BPA-G was detected in neither the maternal nor the fetal placental
circulation 42. In addition to passive diffusion of BPA, there are active placenta transport
proteins such as organic anion transporting polypeptide (Oatp) and multidrug resistance
associated protein (Mrp) transporter family members that aid in the transport of
conjugated BPA

40,43,44

. BPA-G has been shown to cross into the placenta via the

Oatp4a1 transport and then into fetal circulation by Mrp1 transporter 40,44. Thus, BPA has
the potential to reach fetal circulation in both conjugated and active forms.
The fetal liver is reported to have a 36-fold lower level of UGT2B15 than the adult liver,
suggesting that the fetus has a decreased potential to metabolize BPA 40,45,46. While BPAG is considered to be inactive, β-glucuronidase in the fetal liver can deconjugate BPA
into the active form

40,47

. Thus, the risk of BPA to the fetus is compounded by its ability

to de-conjugate BPA-G, as well as by its undeveloped drug detoxifying system

40,46

.

Additionally, since BPA-G is water soluble and cannot cross back through the placenta

9

into maternal circulation after excretion in the fetal urine, it may become trapped in the
amniotic fluid where it has the potential to continually re-enter fetal circulation 47. Thus,
there is growing concern about the risk of the developing fetus to prenatal exposure to
BPA.

10

Figure 1.2: Prenatal pharmacokinetics of BPA
Absorption of BPA occurs in the maternal intestines, BPA can either (1) be metabolized
by the maternal liver to BPA-G, by UGTs, and then transported across the placenta by
transport proteins or (2) freely diffuse across the placenta unconjugated and reach the
fetal circulation. Conjugated BPA in the fetus can be unconjugated by b-Gase by the fetal
liver to unconjugated BPA. Unconjugated BPA can then reach target fetal organs and
accumulate in the fetus. Abbreviations: BPA, Bisphenol A; UGT, uridine 5’-diphosphoglucuronosyltransferase; BPA-G, BPA-glucuronide; b-Gase, β-glucuronidase.
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1.1.4

Human Exposure to BPA

It is estimated that 90-95% of people have detectable levels of BPA in their urine,
demonstrating the universality of BPA exposure

9,15

. Ninety percent of BPA exposure is

thought to result through food and drink exposure, with the remaining exposure through
dust, dental products and surgery, and dermal contact

15

. Health Canada has designated

the level of tolerable daily intake (TDI) of BPA to be 25 µg/kg bw per day for the
average Canadian adult, and in 2010 banned the use of BPA in baby bottles and food
containers 48,49. Even with such regulations in place, estimated BPA daily intake levels in
Canadian infants are reported as 0.22-0.33 µg/kg bw/day and levels in adults have been
estimated at 0.052-0.081 µg/kg bw/day

50

. In the United States, the Food and Drug

Administration (FDA), eliminated the use of BPA in epoxy resins of baby food
containers due to marketplace demands in 2013 49. However, the FDA continues to state
that BPA is safe for consumers at their current levels

49

. Similarly, the European Food

and Safety Authority (EFSA) reported there was no health concern of dietary BPA for
any age group

49

, but as a precautionary measure, reduced the levels of safe BPA

exposure from 50 µg/kg bw/day to 4 µg/kg bw/day, and banned the sale of baby bottles
containing BPA

49

. Nonetheless, government agency regulations aimed at preventing

exposure to BPA in infants and young children do not address the issue of fetal exposure
to BPA during pregnancy via maternal sources, which has been shown to have
permanent, long lasting effects on human health 11,12.

1.1.4.1

Developmental Origins of Health and Disease

Over thirty years ago, David Barker first considered the possibility that poor maternal
malnutrition resulting in low birth weight of the fetus led to premature death due to
metabolic and cardiovascular complications later in life for the offspring 51. This concept
was expanded to include early life exposure to environmental toxins that can lead to
subtle changes during development that lead to dysfunction and/or diseases later in life
and is now referred to as the Developmental Origins of Health and Disease (DOHaD)
hypothesis

51

. Application of this hypothesis to BPA implies that prenatal exposure to

BPA can have long lasting effects that span a lifetime due to alterations in gene and
protein expression that occur during the critical period of organ development

51,52

.

Epigenetic alterations in the fetus are also thought to play an important role in the

12

susceptibility to dysfunction and/or disease later in life

52

. Furthermore, many of these

developmental effects can be sex-specific and are often irreversible

51

. As such,

developmental exposure to environmental stressors (altered nutritional status,
environmental chemical, stress, etc.) can have lasting effects on the offspring, which is
not yet fully understood.

1.1.4.2

BPA during Pregnancy

Dynamic changes occur in drug metabolism and transport during pregnancy, and thus
BPA metabolism may vary in pregnant versus non-pregnant populations

40,53

. During

pregnancy, women have increased plasma volume and clearance as well as altered
metabolism depending on the specific enzymes involved

40,53

. Consequently, there is a

possibility of an increased half-life of BPA in the maternal circulation thereby increasing
potential fetal exposure 47.
While the placenta is considered a protective barrier between the mother and fetus, many
environmental chemicals pass through the placenta due to their high lipophilic properties
54

. Furthermore, the presence of both ERα and ERβ on the placenta make it vulnerable to

estrogenic environmental contaminants such as BPA

54

. The ban of BPA from baby

products (e.g. baby bottles and toys) does not reduce the risk of BPA exposure to the
developing fetus 11,12. Indeed, pregnant German women were found to have plasma levels
of BPA as high as 9.2 ng/mL, and their fetuses had plasma levels of BPA averaging 12.7
ng/mL, proving that BPA crosses the placenta

55

. This finding was supported by North

American and Canadian studies that determined BPA levels in maternal serum to be
between 0.5-22.3 ng/mL 56, and BPA levels in urine from pregnant women to be between
0.16-43.20 ng/mL, respectively
fluid, and breast milk

55,58-60

57

. BPA has also been detected in cord blood, amniotic

. Taken together, these studies show cause for concern about

in utero exposure to BPA during fetal development 13.

1.1.4.3

Fetal Exposure to BPA

One of the major functions of the placenta is to act as a barrier preventing xenobiotics in
the maternal circulation from reaching the fetus 42. However, the placenta appears to be
ineffective at preventing the transfer of BPA, since unconjugated BPA readily crosses the
placenta by passive diffusion in both directions

42,61

. While members of the BPA

13

metabolizing enzyme UGT and SULT families are expressed in the placenta, they have
negligible efficacy in conjugating BPA in this milieu

42

. In addition to its detection in

cord blood, fetal blood, placental tissues, and amniotic fluid

3,42,55

, BPA was found in

fetal tissues, including fetal liver samples (9.02 ng/g unconjugated BPA, 25.8 ng/g total
BPA) collected from the greater Montreal area between 1998 and 2008 62. Thus, BPA is
readily crossing the placental barrier and reaching the fetus.
Various animal models employed to examine the effects of fetal exposure to BPA have
demonstrated that fetal BPA exposure has a wide range of adverse effects including
reproductive, cardiovascular, immunological, metabolic, behavioral, and neurological
disorders; contributes to the development of certain cancers in adult offspring; and that
many of these effects are sex-specific

2,6,13

. In mouse models, pre- and post-natal

exposure to low doses of BPA affected the organization of the central nervous system and
neurotransmitter receptor systems, resulting in reduced and/or reversed sexual differences
in the emotional behavior of offspring

63,64

. Moreover, in this model, low doses, but not

high doses of BPA, resulted in metabolic disruption (increased body weight, adipocyte
number, abdominal fat, insulin levels, and impaired glucose tolerance) in male offspring
63,65

. Our laboratory has demonstrated that prenatal exposure to BPA impairs the

development of the fetal liver

66

, pancreas

67

and lungs

68

. Therefore, due to the

ubiquitous nature of BPA, there is increasing concern for the potential long-term
consequences of developmental exposure to BPA.

1.2

The Adrenal Gland

The adrenal glands are an important endocrine organ that synthesizes hormones in its
cortex and medulla

69,70

. The adrenal cortex produces steroid hormones during fetal and

adult life, including glucocorticoids, aldosterone, progesterone, and precursors of
testosterone and estradiol

69,70

. These hormones are produced via the steroidogenic

pathway, which starts with cholesterol and involves a number of cytochrome P450
enzymes and hydroxysteroid dehydrogenases 69,70.
The adult adrenal cortex is divided into three zones: the zona glomerulosa (ZG), zona
fasciculata (ZF) and the zona reticularis (ZR) 70 (Table 1.1). The outermost adrenal zone,
the ZG, secretes aldosterone and is a key component of the renin-angiotensin-aldosterone

14

axis, which is responsible for the regulation of water balance

71,72

. Aldosterone

transcriptionally regulates a number of proteins and enzymes involved in maintaining
water and sodium balance, and potassium excretion in the kidney

71,72

. Cells of the ZG

contain numerous mitochondria, and some cytoplasmic lipid droplets

71

. The middle

adrenal cortex zone, the ZF, secretes glucocorticoids, a key hormone in the
hypothalamic-pituitary-adrenal (HPA) axis

71

. Cells in the ZF are arranged in bundles,

called fascicles that are surrounded by numerous capillaries 71. These cells contain large
numbers of mitochondria, as well as prominent smooth endoplasmic reticulum and large
lipid droplets used for steroidogenesis

71

. The ZR, the innermost adrenal cortex zone,

secretes dehydroepiandrosterone (DHEA), a precursor of testosterone and estrogens

71

.

Cells of the ZR are similar in shape and size to the ZF but have more lysosomes and
fewer lipid droplets

71

. The adrenal medulla is composed of chromaffin cells that

synthesize epinephrine and norepinephrine

73

. All adrenal gland hormones play various

critical roles in maintaining homeostasis. However, this thesis specifically focuses on the
regulation of adrenal glucocorticoid synthesis.
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Table 1.1: Hormone production in the adrenal cortex.
Zona Glomerulosa

Zona Fasciculata

Zona Reticularis

Stimulus

Angiotensin II

ACTH

ACTH

Primary
Receptor

Angiotensin II
receptor

MC2R

MC2R

Hormone
Product

Mineralocorticoids
(Aldosterone)

Glucocorticoid
(cortisol/corticosterone)

Androgens
(DHEA)

Function

Regulation of
intravascular volume

Glucose homeostasis
Stress response
Immune response

Adrenarche

Abbreviations: ACTH, Adrenocorticotropic hormone; MC2R, melanocortin 2 receptor; DHEA,
dehydroepiandrosterone.
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1.2.1

The HPA Axis

The production of glucocorticoids is regulated by the HPA axis (Figure 1.3)

74,75

. Upon

stimulation, corticotrophin releasing hormone (CRH) is synthesized and secreted from
the paraventricular nucleus in the hypothalamus into the hypophyseal portal vessels to be
transported to the anterior pituitary gland

75

. Binding of CRH to the CRH receptor 1

(CRHR1) in the anterior pituitary gland induces synthesis of adrenocorticotrophic
hormone (ACTH) from the prohormone proopiomelanocortin (POMC)

75

. ACTH is

released into the systemic circulation where it binds melanocortin 2 receptor (MC2R), a
G-protein coupled receptor expressed on the adrenal cortex, to stimulate steroidogenesis
76

. The stimulatory effect of ACTH can increase steroidogenesis in a number of ways

including (1) promoting adrenal cortex growth over the long term
up- regulation of its receptor MC2R

78

77

; (2) promoting the

; (3) increasing the presence of the scavenger

receptor class B member 1 (SRB1) and low-density lipoprotein (LDL) receptors, thereby
enabling enhanced uptake of cholesterol

78

; and (4) up-regulating key steroidogenic

enzymes such as cyp11A1 77,78 and steroidogenic acute regulatory protein (StAR) 78.
The HPA axis is tightly regulated by a glucocorticoid negative feedback mechanism

75

.

Glucocorticoids produced from the adrenal gland provide a negative feedback signal to
the hypothalamus and pituitary gland to inhibit further glucocorticoid production through
altering transcription of HPA components upon binding to glucocorticoid responsive
elements (GREs) or interaction with various transcription factors

75

. Disruptions in the

development and formation of the HPA axis pathways during the critical window of fetal
development has long lasting health consequences that extend into adulthood, including
metabolic syndrome 79 and anxiety/mood disorders 80,81.
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Figure 1.3: Hypothalamic-pituitary-adrenal (HPA) axis.
Hypothalamus releases CRH binding to CRHR-1 receptors on the anterior pituitary gland.
Binding of CRH stimulates the release of ACTH which binds to MC2Rs on the adrenal cortex,
causing the release of glucocorticoids; cortisol in humans and corticosterone in mice.
Glucocorticoids will negatively feedback to both the hypothalamus and anterior pituitary gland to
regulate its expression. Abbreviations: CRH, corticotrophin releasing hormone; CRHR-1,
corticotrophin releasing hormone receptor-1; ACTH, adrenocorticotrophic hormone; MC2R,
melanocortin 2 receptor.
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1.2.2

Physiological Function

Glucocorticoids are essential in maintaining whole body homeostasis through their
various actions in numerous tissues. Glucocorticoids play a major role in glucose
metabolism in stressful environments through increasing serum glucose and amino acids
by (1) increasing catabolism of muscle to increase circulating amino acids; (2) increasing
amino acid uptake in the liver to increase gluconeogenesis and glycogenesis; and (3)
decreasing peripheral glucose uptake in muscle and adipose tissue 78,79,82,83. Additionally,
glucocorticoids increase general catabolism by increasing lipid hydrolysis and increasing
fatty acids and by increasing bone and connective tissue catabolism, which may result in
osteopenia, and thinning of skin and support structures

78,79,82-84

. Glucocorticoids also

play an important role in the immune system by suppressing the inflammatory response
while promoting anti-inflammatory actions 78,85.

1.2.2.1

Cushing’s Disease

Cushing’s disease (CD) is an endocrine disorder characterized by the overproduction of
ACTH due to a pituitary tumor, commonly an adenoma, which results in overstimulation
86-89

of the adrenal gland

. While CD is the most common form of Cushing’s syndrome,

other causes include excessive use of glucocorticoids 86-89. Cushing’s syndrome is defined
by increased cortisol in both the serum and urine, with a disruption of the HPA axis and
cortisol circadian rhythm

86

. The prevalence of CD is reported as 40 cases per million,

and has highest prevalence in women aged 40-60 years old

86

. Symptoms of excessive

glucocorticoids include increased weight gain, fatigue, insulin resistance, skin thinning,
and bruising

86,87,89

. The wide range of comorbidities associated with CD includes

hypertension, diabetes mellitus, dyslipidemia, osteoporosis, depression, impaired sexual
function in men, menstrual disorders in women, and infertility in both men and women
86,88

. Additionally, patients with persistent or recurring CD or excessive glucocorticoid

production have increased risk of mortality 86. Untreated CD has a five-year survival rate
of less than 50%

89

; with the most common causes of mortality being cardiovascular

disease and infection

86,87

. Patients with CD report a significant decrease in their quality

of life, physically, mentally, and emotionally

86-88

. Treatment for CD varies, depending

on the source of the condition, but the first line of treatment is surgery (pituitary and/or
adrenal gland)

86,87

. Pharmacological therapies, including steroidogenesis inhibitors (e.g.
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ketoconazole, metyrapone, etomidate) and glucocorticoid receptor antagonists (e.g.
mifepristone) are used preoperatively or for reoccurrences

87

. Treatment of CD may

reduce symptoms of the disease, but comorbidities may be irreversible, therefore
potential risk persists throughout life 88.

1.2.2.2

Addison’s disease

Opposite to adrenal over-activity is adrenal insufficiency, often known as Addison’s
disease, which is a rare chronic endocrine disease that results in loss of adrenal function,
with a subsequent decrease in adrenal production of glucocorticoids, as well as
mineralocorticoids in certain cases
secondary adrenal insufficiency

90,91

90-92

. Adrenal insufficiency is classified as primary or

. Primary insufficiency, which affects 0.01% of the

population, results from direct inhibition of glucocorticoid production from the adrenal
gland. Primary adrenal insufficiency can be caused by autoimmune adrenalitis, infectious
adrenalitis (e.g. AIDS, tuberculous adrenalitis), bilateral adrenal hemorrhage, adrenal
infiltration, adrenalectomy, drug-induced adrenal insufficiency, or various genetic
disorders (mutations in any of the adrenal steroidogenic enzymes, regulatory transcription
factors, or receptors)

90,91

. Secondary adrenal insufficiency has a prevalence of 1 in 5,000

and is a result of decreased stimulation of adrenal gland steroidogenesis due to decreased
ACTH levels

90,91

. This can be a result of tumors of the pituitary gland or hypothalamus,

chronic glucocorticoid use, head trauma, isolated congenital ACTH deficiency,
proopiomelanocortin-deficiency, or combined pituitary-hormone deficiency

90,91

. Adrenal

insufficiency presents with a range of symptoms depending on whether the adrenal
insufficiency involves decreased glucocorticoids, mineralocorticoids, and/or androgens .
92

Common clinical manifestations of both primary and secondary adrenal insufficiency
include fatigue, anorexia, muscle weakness, weight loss, light-headedness, nausea,
vomiting, headache, sweating, salt craving, and, in women, dry itchy skin and loss of
libido

90-92

. In addition, adrenal insufficiency can result in an adrenal crisis

90,92

, which is a

severe lack of glucocorticoids during extreme stress, infection, or trauma, and can be life
threatening . Monitoring of glucocorticoid levels and adjustment during times of stress
90

can prevent adrenal crisis, but mortality rates are still 1.5-2 fold higher in patients
suffering from adrenal insufficiency . Current treatment of adrenal insufficiency is to
90

compensate for the glucocorticoid and mineralocorticoids deficiency (only in primary
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adrenal insufficiency), with multiple daily tablets of hydrocortisone or prednisone and
fludrocortisone in doses that mimic normal hormone secretion patterns

91,92

. Primary

adrenal insufficiency results in a decrease in lifespan of 3.2 years in women and 11.2
years in men, compared to the general population, mainly due to increased acute adrenal
failure, infections, and sudden death . People suffering from adrenal insufficiency report
92

a decreased perception of health status and quality of life .
92

1.2.2.3

Adrenocortical Cancer

Adrenal cortical tumors (ACTs) are classified as either malignant adrenal cortical
carcinomas (ACCs) or benign adrenal adenomas (ACA) 93,94. Small ACA’s are relatively
common, affecting about 3-10% of the population 94. In contrast, ACCs are a rare form of
cancer with an annual incidence rate of between 1 to 2 million 93,94. These tumors present
with an aggressive phenotype and the patients have a poor prognosis

94,95

. They are

characterized by altered production of steroid hormones, uncontrolled tumor growth and
metastases to other tissues 95. Between 50-80% of patients present with hypercortisolism
and 40-60% of patients present with excess adrenal androgen production 94.
Numerous genetic mutations and alterations have been linked to the development of
ACTs

95

. Mutations in TP53 predisposes children to pediatric ACTs (as well as other

conditions). This is particularly relevant in southern Brazil, which has a 10-fold higher
rate of pediatric ACTs due to mutations in TP53

96

. Levels of insulin growth factor II

(IGFII) is commonly used as an ACC marker due to its overexpression in 90% of ACCs
95,97

. Alone, mutations that result in increased IGFII levels are not a significant factor for

ACC development, but these mutations may contribute to ACC progression in
combination with other factors

95,98

. Activating mutations of b-catenin, leading to

increased activation of Wnt signaling, has been detected in ACC patients

95,99

.

Additionally, mutation in genes shown to regulate or be involved in Wnt signaling
potentially lead to an increase in ACTs

95

. Mutations in other genes including multiple

endocrine neoplasia 1 (MEN1), mutL homolog 1 (MLH1), mutS homolog 2 (MSH2),
mutS homolog 6 (MSH6), post meiotic segregation increased 2 (PMS2) and post meiotic
segregation increased 2 (PRKAR1A) have all been observed in patients with ACCs 95.
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Alterations in gene expression in ACTs are commonly divided between ACC and ACA
95

. Changes in gene expression frequently seen in ACC are the overexpression of cell

proliferation and cell cycle genes, such as cyclin E1, cyclin E2, and cyclin dependent
kinase 2 and 4 (CDK2 and 4) 95,100. Additionally, ACCs have alterations of steroidogenic
enzymes, including cyp11A1, StAR, cyp17A1, while these enzymes are generally
upregulated in ACAs
101

95

. Other pathways known to be affected in ACTs include, IGFII

, sonic hedgehog (Shh)

102,103

, Wnt

95,99

, fibroblast growth factor receptor (FGFR)

101

,

and retinoic acid signaling pathways 101.

1.2.3

Adrenal Development

The adrenal gland is developed from two different cells types: the adrenal medulla arises
from neural crest cells, while the adrenal cortex arises from coelomic epithelium
(urogenital ridge) (Figure 1.4)

104

. The adrenogonadal primordium develops from the

coelomic epithelium, with the presence of developmental regulatory factors, Wilm’s
tumor 1 (WT-1), and wingless-related mouse mammary tumor virus integration site 4
(WNT4)

104

. In mice, at embryonic day 9 (E9), the key developmental factors

steroidogenic factor-1 (SF-1) and dosage-sensitive sex reversal-adrenal hypoplasia
congenital critical region on the X chromosome factor 1 (DAX-1) can be detected in the
adrenogonadal primordium

104,105

. Migration of adrenal progenitor cells from the

adrenocortical primordium, happens in parallel to an upregulation of SF-1

71,95

. The

importance of SF-1 in adrenal development is demonstrated in studies utilizing knockout
mice, where SF-1-/- mice lacked adrenal glands and died at birth due to adrenal
insufficiency

106

. The expression of steroidogenic enzymes begins at E11 in mice,

indicating the possibility of steroidogenesis

105

. At approximately E12-14, neural crest

cells migrate and disperse into the developing adrenal gland, preceding their development
into the chromaffin cells of the adrenal medulla 107. Encapsulation of the adrenal cortex is
completed by E14.5

104,105

days (PND) 1-7 in mice

, and adrenal cortex zonation is completed between postnatal
105

. The formation of the X-zone surrounding the adrenal

medulla develops between PND10-14 in mice, and continues to proliferate until PND21
105

. The function of the X-zone and its presence postnatally is still not fully understood

105

. In male mice, the X-zone will disappear at sexual maturity, whereas in females, it

22

remains until the first pregnancy

105

. Encapsulation of the medulla by a fibrous tissue

layer is completed only after complete regression of the X-zone 105.
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Figure 1.4: Adrenal gland development in mice.
Urogenital ridge separates into either the (2a) fetal kidney or (2b) the adrenogonadal
primordia, which derives into the (3a) bipotenial gonads or the (3b) adrenal primordia,
where steroidogenic enzymes are first detected at E11. Followed by (4) neural crest cells
migration at E12-14. (5) Zonation occurs at PND1-7, and (6) X-zone development at
PND14-21. (7) Medulla encapsulation and X-zone regression occurs at sexual maturity in
males and at the first pregnancy in females. Abbreviation: E, embryonic day; PND,
postnatal day.
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While development of the adrenal gland in humans differs from that of the mouse in
terms of timing of developmental processes, the factors responsible for adrenal gland
development are thought to be similar between the two species (Table 1.2)

105

. In

humans, migration of coelomic epithelial cells starts during week 5-7 of pregnancy, and
the formation of the fetal zone, which produces DHEA, begins at week 7

105,107

. Despite

considerable differences in timing of development, the fetal zone in humans is thought to
be equivalent to the X-zone in mice
weeks

105,107

105

. The adrenal primordia develops at around 8

. At 9 weeks, migration of mesenchymal capsular cells to encapsulate the

adrenal cortex and neural crest cells to form the adrenal medulla

95,105

. Regression of the

fetal zone takes place shortly after birth (postnatal weeks 1-6), followed by the
encapsulation of the medulla (postnatal months 12-18)

105,107

. Complete adrenal cortex

zonation follows later, around the time of puberty in both males and females (10-20
years) 105.
Estrogen and ERs are thought to play critical roles in the development of the adrenal
gland 108. The discovery of both ERa and ERb in the fetal adrenal cortex suggests a role
for estrogens in regulating adrenal development and function

108

. Upon binding to Ers,

estrogens induce direct and indirect effects in the fetal adrenal gland, affecting sensitivity
and responsiveness to ACTH, and altering the synthesis of DHEA

108,109

. However, the

role of estrogens or Ers in programming glucocorticoid synthesis in the fetal adrenal
gland remains elusive.
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Table 1.2: Human and mouse adrenal development.
Human

Mouse

Migration of coelomic epithelial
cells

5-7 weeks

E9

Development of the adrenal
primordia

8 weeks

E11

Migration of neural crest cells

8 weeks

E12-14

Regression of fetal zone/X-zone

Postnatal week 1-6

PND35 (males), after
first pregnancy
(females)

Medulla Encapsulation

Postnatal month 12-18

PND35

Adrenal Cortex Zonation

10-20 years

PND1-7

Abbreviations: E, embryonic day; PND, postnatal day.
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1.2.4

Adrenal Remodeling and Growth

Differentiation and renewal of the adrenal cortex zones is not fully understood. However,
a few theories have been proposed for adrenal zonation: (1) Migration Theory that
hypothesizes the centripetal proliferation of cells from the outermost zone, ZG, towards
the ZF, then the ZR and finally undergoing apoptosis at the edge of the adrenal medulla;
(2) Transformation field theory that postulates the presence of two transformation fields
between the ZG and ZF and between the ZF and ZR, where proliferation and
differentiation occurs; (3) Zonal theory that proposes that all proliferation in each zone
comes from cells located in the same zone
theory

95,107,111,112

110,111

. The most probable theory is migration

, which posits that proliferation begins with specialized cells located

peripherally in the cortex and that these cells will transit inwards through the cortex
layers, and finally to the medulla border where they undergo apoptosis, a process referred
to as centripetal displacement

111,112

. This process and the location of specific stem cells

varies in rats, where these cells are likely located in an undifferentiated cell zone (zU),
between the ZG and ZF

111

. Continued remodeling and growth is essential in the adrenal

gland after birth and throughout life 112-114. These progenitor cells are not only important
for the development of the adrenal cortex, but also are involved in adrenal cortex
remodeling in adults 112-114.
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1.2.4.1

Hedgehog Signaling

The Hedgehog (Hh) signaling pathway is essential in embryogenesis, adult remodeling
homeostasis, and carcinogenesis in a variety of tissues

115

. The Hh signaling pathway

regulates genes involved in proliferation, the stem-cell signaling network, stem-cell
markers, survival, and epithelial-to-mesenchymal transition 115.
The Hh secretory proteins were first discovered in Drosophila for their role in specific
embryonic segmentation

116

. The three main mammalian HH genes are Sonic hedgehog

(Shh), Desert hedgehog (Dhh), and Indian hedgehog (Ihh). All are critical for
development, as demonstrated in loss of function studies that result in structural
abnormalities and malformations 116,117. Dhh is localized mainly to the gonads, including
Sertoli cells and granulosa cells. While Dhh-/- mice are viable and do not have a notable
phenotype, males are infertile 117. Ihh expression is limited to the primitive endoderm and
prehypertrophic chondrocytes, resulting in 50% lethality in knockout mice, with
surviving Ihh-/- mice having bone abnormalities, including cortical bone defects and
aberrant chondrocyte development

117

. Shh is more broadly expressed both during

embryogenesis and later life 117. Mutations in Shh have been shown to cause cyclopia, as
well as defects in the foregut and ventral neural tube patterning 117. Additionally, defects
present later in life as malformations of the limbs, ribs, and lungs 117.
All Hh secretory proteins bind to the Hh receptors, Patched (Ptch) 1 and 2 to activate the
signaling pathway (Figure 1.5). Patched is a 12-pass transmembrane receptor located on
the primary cilium of target cells. Co-receptors of the Hh signaling pathway include
CDON, BOC, and GAS1

115

. When not bound, Ptch inhibits another transmembrane

protein, smoothened (SMO), by keeping it sequestered in the plasma membrane

117-119

.

SMO is a 7-pass G-protein coupled receptor that is also located in the plasma membrane
of the primary cilium. In the plasma membrane SMO is tethered to a complex containing
the key Shh transcription factors Gli

117-119

. When the Shh pathway is activated, Hh

prevents Ptch from inhibiting SMO and enables the translocation of SMO into the
cytoplasm

117-119

. Upon SMO translocation, the complex containing the Gli transcription

factors are released. In mammals, there are three Gli transcription factors (Gli1-3), with
various activities

117-119

. Gli1 and Gli2 are primarily activators of the Shh signaling

pathway and have similar roles

117-119

. However, Gli1 is also responsible for positive
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feedback of the Shh signaling pathway, and is a direct transcriptional target of Shh
activation, to extend cellular response 117-119. The activation of SMO blocks proteolysis of
Gli1 and 2, which leads to accumulation of the full-length activator forms of Gli1 and
Gli2, ultimately leading to transcription of target genes

117-119

. Gli3 is primarily a

repressor; in the absence of Shh, Gli3 is cleaved into an active repressor form, to inhibit
transcription of target genes, but the presence of Shh prevents Gli3 cleavage and thus
inhibits Gli3 activity

117-119

. Additional factors known to be involved in the regulation of

the Shh pathway include suppressor-of-fused protein (Su(fu)) and hedgehog interacting
protein (Hhip), both of which attenuate Shh signaling 115,118.
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Figure 1.5: Simplified schematic of the Shh signaling pathway activation.
The secretory protein Shh, acts in an autocrine/paracrine fashion and binds to Ptch1
receptor, preventing Ptch1 from inhibiting SMO. SMO is then released from the plasma
membrane into the cytoplasm, leading to the release of key Shh transcription activators
Gli1 and Gli2. Gli1/2 translocate to the nucleus where they bind to the promoters of
target genes to regulate gene expression. Abbreviations: Shh, sonic hedgehog; Ptch1,
Patched 1; SMO, smoothened.
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Due to the importance of Shh signaling in development and organ remodeling later in
life, the Shh signaling pathway has been investigated in both rodent and human adrenal
glands. Expression of mRNA for Shh, Ptch1, and Gli1 begins at E12.5 in the mouse
adrenal cortex, and is localized in clusters at the periphery of the adrenal cortex, which
continues throughout development

112,114,120

. Shh, Gli1, 2, and 3 proteins are detected

throughout development and postnatally in the fetal human adrenal gland, with higher
expression than is found in adult human adrenal glands

102

. In contrast, Werminghaus et

al. demonstrated undetectable levels of Shh protein in both normal adult adrenal glands
and adrenocortical carcinomas and adenomas

103

. However, protein levels of Gli1 were

detectable in all adrenal cortex zones, but concentrated in the subcapsular area of the ZG
of human adult adrenal glands, and was not detectable in adrenocortical carcinomas or
adenomas 103. While additional studies have also detected mRNA for Shh, Gli1, 2 and 3,
Ptch1 and SMO in human adrenal glands, adrenocortical carcinomas and adenomas
102,103

. Additionally, there was an upregulation of SHH in both cortisol producing and

non-cortisol producing adrenal adenomas compared to normal adrenal tissues, suggesting
that Shh activation is involved in adrenal tumorigenesis

102,103

. Moreover, Shh, Gli1,

Ptch1 and SMO mRNA has been found in human adrenal cortical carcinoma cell lines,
H295R and H295A102,103. The presence of Dhh or Ihh in the adrenal glands has yet to be
determined 113.
Shh and Shh pathway components (Ptch1, SMO, Gli1) mRNA and protein are localized
in the outer cortex cells, which do not express the steroidogenic enzymes cyp11b1 or
cyp11b2, during early organogenesis and throughout adulthood in mice 112. This indicates
the presence of a specialized population of cells in the adrenal cortex that lacks the ability
to produce steroid hormones

112

. This demonstrates the essential role of Shh signaling in

the development and expansion of the adrenal cortex

114

, and supports the theory of

adrenal growth and remodeling through a centripetal displacement process, where Shh
containing cells are progenitor cells that differentiate into steroidogenic cells (Figure 1.6)
112,113

. Indeed, previous studies using genetic lineage analyses performed using a

constitutive Cre model, demonstrated that Shh-positive cells give rise to cortex cells in all
zones except the medulla

112

. Moreover, lineage analysis in adults, shows that cells
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transition from the outer ZG to the ZF, demonstrating that Shh marks progenitor cells in
the adrenal cortex during development and remodeling in adults 112,113.
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Capsule
Progenitor cells
ZG

ZF

X-zone
Medulla

Figure 1.6: Migration theory of adrenal gland remodeling in mice.
Progenitor cells (purple), which are Shh+/Sf-1+/cyp11B2-, signal to Gli1+/cyp11B2capsule cells (red), to differentiate into functional ZG steroidogenic cells (orange). The
migration theory suggests a centripetal displacement process where ZG cells move
inward and differentiate into ZF cells (blue) and on to X-zone cells (dark red), before
undergoing apoptosis at the medulla border. Abbreviations: Shh, sonic hedgehog; Sf-1,
steroidogenic factor-1; ZG, zona glomerulosa, ZF, zona fasciculata.
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Gli3 mutation was found to be lethal in embryonic mice and to have an adrenal aplasia
phenotype

121

. However, this phenotype was not observed by Laufer, et al.

113

. Adrenal

Shh conditional knockout mice, created with a Sf-1-cre driver, exhibit severe hypoplasia
and underdevelopment of the adrenal gland, but have no changes in zonation or
differentiation of the adrenal cortex 112,114,120. There was a significant decrease in both the
thickness of the adrenal cortex and the capsule in these mice

112,114

. These effects were

visible as early as E13.5, with no visual changes to the adrenal medulla

112,114,120

.

However, despite the reduction in cortex size, the expression of steroidogenic enzymes
was unaltered in Shh-/- mice

112,114,120

. Corticosterone levels were normal until

approximately one year of age, when they became reduced along with an increase in
ACTH plasma levels 114. Moreover, Shh-/- mice had reduced levels of proliferating cells in
their adrenal cortex, with no change in apoptosis levels 114. In H295R cells, blocking Shh
signaling with the antagonist cyclopamine resulted in decreased proliferation, and
decreased production of aldosterone and DHEA 103.

1.2.4.2

Wnt-1 Signaling

In both fetal and adult adrenal glands, the Wnt/b-catenin signaling pathway is critical for
adrenocortical homeostasis

122

. b-catenin is present in the fetal adrenal cortex, and is

localized to the ZG subcapsule

122

. Mice null for b-catenin in SF-1 expressing adrenal

cortex cells, show abnormal adrenal development starting at E12.5, resulting in adrenal
failure

123

. b-catenin Sf-1-cre mice, which expressed b-catenin in approximately half of

their adrenal cortex cells, developed normally

123

. However, a thinning of the adrenal

cortex and decreased steroidogenic function was observed starting at 30 weeks of age 123.
Additional evidence for the role of Wnt-1/b-catenin signaling in adrenal development and
function is demonstrated when the signaling pathway is over-activated

123,124

.

Constitutive over-activation of b-catenin results in increased proliferation of
undifferentiated progenitor cells, with the eventual development of ACTs

123,124

.

Activation of the Wnt signaling pathway is commonly seen in adrenocortical neoplasms
125,126

. The exact mechanism of Wnt/b-catenin signaling in adrenal cortex function and

development remains unknown

107

. However, potential mechanisms include direct

activation of Dax1 by b-catenin 127 and b-catenin induced inhibition of ZF differentiation,
supporting the undifferentiated phenotype of progenitor cells 126,128.
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1.2.5

Sex Specificity in Adrenal Glands

Female adrenal glands are significantly heavier than those of male mice from weeks 3-11,
relative to body weight

129

. Additionally, female mice have a significantly larger ZF size

and cell number compared to male mice after 3 weeks of age

129

. Both sexes have an X-

zone until approximately week 5 postnatally, when the X-zone starts to recede in male
mice 129. In female mice, the X-zone persists until after the birth of their first litter, when
it will start to recess. However, the role of X-zone and the sex-specificity of this zone is
not fully understood yet 105. Studies investigating corticosterone levels between sexes in a
variety of species including humans have reached different conclusions with some
reporting sex differences in corticosterone levels 78,130, while others found no differences
in corticosterone levels between sexes

129,131-133

. Species investigated, time of collection,

method of collection, and age of animal may all be confounding factors, contributing to
the disagreement between the studies. Females are commonly shown to have a higher
corticosterone response to stress, which is also sustained longer than it is in males

78

.

Additionally, female mice have a greater number of lipid droplets stored in the adrenal
glands than their male counterparts

129

, which indicates a potential for different

steroidogenic activity and capabilities. Additionally, levels of plasma corticosteroid
binding globulin (CBG) vary between sexes, due to role of estrogen in promoting
synthesis of CBG 78. After puberty females are reported to have 2 to 5-fold higher CBG
levels than males

78

. Thus, there are numerous sex differences in the growth and

development in the adrenal gland, but the exact mechanism behind these differences
remains largely unknown.

1.3
1.3.1

Adrenal Steroidogenesis
Steroidogenic Pathway

Steroidogenesis is the synthesis of all steroid hormones by a variety of P450 enzymes and
hydroxysteroid dehydrogenases, generally located in the adrenal glands, placenta, and
reproductive organs

69

. However, low levels of steroidogenesis have been reported in

other tissues134, such as the nervous system

135

, skin136, heart

137

, and lungs

138

. The

steroid hormones produced in each organ is dependent on the specific steroidogenic
enzymes expressed in that organ 69.
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The initial step of adrenal steroidogenesis begins in the adrenal cortex, where cholesterol
is necessary to produce steroid hormones (Figure 1.7). Most cholesterol for adrenal
steroidogenesis originates from either high-density lipoprotein (HDL) or LDL in the
blood and transport of cholesterol into the cell is mediated by SRB1 receptors for HDL or
LDL receptors for LDL

77

. Humans preferentially utilize cholesterol from LDL

endocytosis, while rodents use cholesterol transported by SRB1 receptors

77

. Additional

free cholesterol can be produced from de novo synthesis, primarily from the endoplasmic
reticulum

77

. Cholesterol in endosomes can be converted into free cholesterol by

lysosomal acid lipase (LAL)

77,139

. Free cholesterol can be released from cholesterol

esters stored in lipid droplets by hormone sensitive lipase (HSL)

77,139

. Re-esterified

excess free cholesterol by acyl-coenzyme-A-cholesterol-acyl-transferase (ACAT) can be
stored in lipid droplets for future use 77.
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Figure 1.7: Cholesterol transport for adrenal steroidogenesis.
Free cholesterol for adrenal steroidogenesis is generated by 4 sources. (1) de novo
synthesis from the endoplasmic reticulum; (2) LDL binding to the LDL receptor, which is
taken up by endocytosis into lysosomes, where it will be synthesized from cholesterol
esters to free cholesterol by LAL; (3) HDL cholesterol will bind to SRB1, which can be
immediately used for steroidogenesis or stored in lipid droplets; or (4) HSL provides free
cholesterol from lipid droplets. Excess cholesterol can be stored in lipid droplets after
esterification by ACAT. Abbreviations: LDL, low-density lipoprotein; LAL, lysosomal
acid lipase; HDL, high-density lipoprotein; SRB1, Scavenger receptor B type 1; HSL,
hormone sensitive lipase; ACAT, Acyl-coenzyme-A-cholesterol-acyl-transferase.
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Within the adrenal cortex cells, steroidogenesis begins within the mitochondria. The ratelimiting step of adrenal steroidogenesis is the transport of free cholesterol from the outer
mitochondrial membrane (OMM) to the inner mitochondria membrane (IMM), which is
facilitated by the protein StAR (Figure 1.8)

140

. Once cholesterol is in the mitochondria,

it can be converted to pregnenolone by the P450 enzyme, cyp11A1 (formally referred to
as P450 side chain cleavage; P450scc). Cyp11A1 conversion is a process of 3 reactions
(1) 22-hydroxylation of cholesterol; (2) 20-hydroxylation of 22(R)-hydroxycholesterol;
and (3) oxidative scission of the C20-22 bond

77,141

. Conversion of cholesterol to

pregnenolone is critical for the production of all steroid hormones, so knockout of
cyp11A1 or mutations in this gene result in loss of steroidogenic activity

141

. For the

synthesis of glucocorticoids, pregnenolone is converted to progesterone by 3βhydroxysteroid dehydrogenase (3β-HSD). In primates that synthesize mainly cortisol but
also low levels of corticosterone, Cyp17 converts pregnenolone to 17a-hydroxylase
pregnenolone and converts progesterone to 17a-hydroxylase progesterone. Progesterone
or

17a-hydroxylase

progesterone

will

then

be

further

converted

to

11-

deoxycorticosterone or 11-deoxycortisol by Cyp21 in rodents and humans, respectively
69

. Finally, corticosterone/cortisol will be synthesized from 11-deoxycorticosterone/11-

deoxycortisol by an adrenal specific P450 enzyme, Cyp11B1. Corticosterone/cortisol can
either exit the adrenal gland in the plasma, bound to CBG and transported to most target
organs throughout the body

78

the ZG of the adrenal cortex

142

or can be further converted by Cyp11B2 to aldosterone in
.
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Figure 1.8: Steroidogenic pathway involved in glucocorticoid synthesis.
Steroidogenesis starts with the transport of free cholesterol from the outer mitochondria
membrane to the inner mitochondria membrane by StAR, which can then be further
converted to all the major steroid hormones. Abbreviations: StAR, steroidogenic acute
regulatory protein; cholesterol side chain cleavage enzyme, cyp11A1, 3β-HSD, 3βhydroxysteroid

dehydrogenase;

cyp21,

21-hydroxylase;

cyp11b1,

steroid

11β-

hydroxylase; cyp11b2, aldosterone synthase; cyp17, cytochrome P450 17A1; cyp19,
aromatase; 17β-HSD, 17β-hydroxysteroid dehydrogenases.
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1.3.2

Steroidogenic Acute Regulatory Protein

StAR is the rate-limiting step in steroidogenesis, due to its essential role of transporting
cholesterol from the OMM to the IMM for steroidogenesis. Mutations of StAR in humans
produce congenital lipoid adrenal hyperplasia, resulting in a lack of steroid hormone
production that requires life-long hormone therapy

143

. Moreover, StAR knockout mice

lack the ability to synthesize steroid hormones, and accumulate cholesterol in both the
adrenal glands and gonads

144-147

. StAR-/- mice have external female genitalia and fail to

grow after birth 147. A proportion of StAR-/- mice die shortly after birth due to respiratory
distress, and the remainder die a week after birth from an imbalance in fluid and
electrolytes, a result of secondary adrenal insufficiency

147

. While StAR-/- mice can be

rescued by treatment with steroid hormones (corticosterone and aldosterone), they retain
notable abnormalities in adrenal and gonad structure and function
not completely abrogated in StAR

-/-

146

. Steroidogenesis is

mice until the accumulation of lipid droplets in

adrenal and gonads builds up enough to destroy steroidogenic cells 146.
StAR originates from a 37-kDa StAR pre-protein with an N-terminal mitochondrial
targeting sequence that directs it to the mitochondria 77,141. The 37-kDa StAR cytoplasmic
precursor has a short half-life, and is rapidly degraded if not imported into the
mitochondria (Figure 1.9) 141. Cleavage of the 37-kDa StAR pre-precursor into a 30-kDa
“mature” molecule by removal of the N-terminus occurs at the OMM

148

. Although the

30-kDa protein (referred to in this thesis only as StAR) is considered “mature”, the
removal of the N-terminus is not necessary for activation

77

. The cleavage, however,

seems to contribute to the localization of StAR on the OMM, which does determine its
activity

77,149

its activity

. Thus, the time of StAR residency on the OMM is directly proportional to

77,141

. StAR contains a sterol binding pocket allowing it to transport a single

cholesterol molecule from the OMM to the IMM. 150. However, each StAR molecule will
transport hundreds of cholesterol molecules before it undergoes cleavage and removal
from the OMM, terminating its activity

141

. There are currently four proposed models to

account for StAR’s ability to transport cholesterol

151

. (1) Contact sites: the 37-kDA

StAR forms contact sites with the OMM and IMM that permit cholesterol to flow down a
concentration gradient into the mitochondrial matrix

151,152

. (2) Desorption: StAR

“desorbs” cholesterol at the OMM, permitting its entry into the intra-mitochondrial space
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(IMS), potentially as micro droplets 151,153. There is little evidence to support this theory,
since micro droplets of cholesterol have not been observed 151. (3) IMS Shuttle: StAR acts
in the IMS to shuttle cholesterol from the OMM to the IMM

151,154

. This theory is no

longer accepted, due to the observation of StAR activity on the OMM

151

. (4) Molten

Globule: StAR undergoes a conformational change at the OMM caused by protonated
phospholipids 149,151. This is confirmed by the dependence of StAR on a proton pump on
the mitochondria for its activity

151,155

. Additionally, at the OMM StAR interacts with a

multi-protein complex containing translocation protein (TSPO, previously the peripheral
benzodiazepine receptor; PBR), voltage-dependent anion channel 1, and phosphate
carrier protein, which may all be involved in StAR-mediated cholesterol transport
148,149,156,157

. The activity of steroidogenesis is partially controlled by the phosphorylation

of StAR at Ser194/5, which doubles its rate of cholesterol transport

77,158

. In the absence

of StAR, steroidogenesis is possible when cholesterol transport occurs with the help of
metastatic lymph node 64 protein (MLN64) using a yet to be determined mechanism 159.
This MLN64 mediated process of cholesterol transport occurs mostly in the human
placenta, which lacks StAR protein, and has about 50-60% of the cholesterol transport
ability of StAR 159.
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Figure 1.9: Synthesis of steroidogenic acute regulatory protein (StAR).
(1) Transcription of StAR occurs in the nucleus of steroidogenic cells. (2) StAR mRNA
is then transported to the mitochondria where it binds to AKAP149, which is involved in
its translation into a 37-kDa pre-protein and phosphorylated by PKA at Ser194/5. (3) 37kDa StAR will then interact with the multi-protein complex, TSPO on the outer
mitochondria membrane, where the n-terminus of StAR is cleaved. StAR then facilitates
the transport of cholesterol from the outer mitochondria membrane to the inner
mitochondria membrane. (4) After cholesterol transport, 30-kDa StAR will enter the
mitochondria where it will be degraded. Abbreviations: StAR, steroidogenic acute
regulatory protein; AKAP149, A-kinase anchor proteins; PKA, protein kinase A; TSPO,
Translocator protein.
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1.3.2.1

Regulation of StAR

Due to the essential role of StAR in facilitating cholesterol transport from the OMM to
the IMM for steroidogenesis, the regulation of this protein is of great importance. The
regulation of StAR is not fully understood but has been shown to be quite complex,
involving numerous hormones, transcription factors, and receptors 160,161.

1.3.2.1.1

Epigenetic Regulation of StAR

StAR expression is affected directly and indirectly by epigenetic modifications, such as
histone modifications, and micro-RNA (miRNA) 162-166. For example, induction of StAR
was associated with acetylation of histone 3 but not histone 4 on the proximal StAR
promoter in MA-10 cells and in primate granulosa cells after stimulation

162,163

.

Additionally, epigenetic factors can have indirect effects on StAR expression by altering
transcription factors known to bind the StAR promoter, such as miRNA-133b inhibition
of the negative transcription factor forkhead box L2 (Foxl2), which results in increased
StAR transcription 164.

1.3.2.1.2

Transcriptional Regulation of StAR

The first 150 bases of the proximal StAR promoter are highly regulated by numerous
transcription factors. Positive regulators of StAR transcription include SF-1, CCAATenhancer-binding protein β (C/EBPβ), GATA-4, specificity protein 1 (Sp1), sterol
regulatory element binding protein (SREBP), CREB/CREM, and AP-1
which have numerous putative binding sites on the StAR promoter

140,162,167

140,167

, all of

. Additionally,

DAX-1, Foxl2 and Yin Yang 1 (YY1) negatively regulate transcription of StAR mRNA.
Transcription factor expression and regulation of StAR have been shown to be cell/tissuespecific as well as time dependent 162.
SF-1 not only plays a critical role in adrenal development, it is also known as a master
regulator of steroidogenesis

168

. There are six binding sites for SF-1 on the StAR

promoter, where it can regulate both basal and stimulated StAR transcription

140,167

. The

SF-1 binding sites -43/-37, -102/-96 and -105/-99 have all been shown to be essential for
both basal and stimulated StAR regulation in reproductive cells 167. Mutations in any SF1 binding sites, result in a significant decrease, but not an elimination in cAMP induced
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StAR activity, demonstrating the involvement of other transcription factors or regulatory
responses in StAR expression.
These transcription factors are able to act alone or in combination by binding to the StAR
promoter

167

. It is suggested that C/EBPβ can form a complex with SF-1 on the StAR

promoter, as well as interacting with Sp1 to promote StAR transcription

140,167

.

Additionally, SF-1 can interact with Sp1, and C/EBPβ cooperates with GATA-4 to
regulate StAR expression,

167

. Therefore, the regulation of StAR transcription is thought

to involve the interaction of numerous transcription factors at the StAR promoter region.

1.3.2.1.3

Post-transcriptional Regulation of StAR

Initially, StAR was thought to be mainly transcriptionally regulated, however recent
evidence points to a role of post-transcriptional regulation of StAR

160

. The stability of

StAR mRNA and post-translational regulation of StAR have been investigated

160

.

Currently, no known proteins have been shown to bind to StAR mRNA to regulate its
stability, however, possible candidates include the mRNA stabilizing proteins, TPAinduced sequence 11b (Tis11b) and HuR, which are expressed in steroidogenic cells 160.
Additionally, StAR mRNA may be targeted by proteins such as mevalonate kinase,
DAX-1 and A-kinase anchoring protein 121/149 (AKAP121/149) that alter its rate of
translation . AKAP121/149 contains an N-terminal KH domain that targets and recruits
160

StAR mRNA to its location at the OMM where it can be translated . StAR protein
169

expression at the OMM has been shown to be enhanced by AKAP121/149 in MA-10
cells

170

. In addition, AKAP121/149 has been demonstrated to recruit PKA, which

phosphorylates StAR to increase its activity .
170

The N-terminal of the 37-kDa StAR directs it to the mitochondria, but it may also
destabilize the protein, promoting its degradation and contributing to its short half-life
152,160

. StAR degradation in the cytoplasm has been shown to be extremely rapid in many

tissues

171

. Proteasome-mediated degradation of the 37-kDa StAR protein has been

demonstrated, and it is suggested that this may occur without ubiquitinylation of StAR .
171

StAR physically and/or functionally interacts with numerous proteins at or around the
OMM, including cyclin dependent kinase-5 (CDK5), mitochondrial kinases (MEK) 1/2,
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PAP7, TSPO, HSL . While these proteins and others could potentially contribute to
160

StAR’s expression and activity, more evidence is needed to understand StAR–protein
interactions.

1.4
1.4.1

Effects of BPA on Steroidogenesis
Male Reproductive Steroidogenesis

Due to its estrogenic nature, the effect of BPA on the male reproductive system has been
the subject of considerable research effort. BPA exposure, both during the prenatal period
and during adulthood results in increased prostate size

6,172

. Rodent studies have

demonstrated that exposure to BPA during the developmental period alters
spermatogenesis and reduces sperm quality in adult offspring

173

. Additionally, BPA

adversely affects androgen production, which is essential for functional spermatogenesis
173

. Decreases in testosterone levels and/or steroidogenic enzymes was observed in

rodents exposed to BPA prenatally, as well as during the postnatal period 173-176.
Investigation of the effects of BPA on the rate limiting step of steroidogenesis, StAR, in
the male reproductive system yielded inconsistent results that vary between model
systems (Table 1.3 and 1.4). In male rats, Qui et al. 2003

177

observed an increase in

StAR and cyp11A1 gene expression in the testis after acute BPA exposure. In contrast,
D'Cruz, et al.

175

demonstrated that BPA exposure resulted in decreased protein

expression of StAR in male rats, a finding in agreement with two other studies showing
that acute BPA exposure decreased StAR levels in testes

174,178

. Chouhan, et al.

178

concluded that the decrease in StAR protein after BPA exposure could be attributed to a
BPA-induced increase in oxidative stress, resulting in increased inducible nitric oxidative
synthase (iNOS). Moreover, both perinatal and acute exposure to BPA significantly
inhibited StAR in the testis of fetal and offspring rodents 179-181. However, BPA treatment
for 17 h did not significantly alter levels of StAR in primary mouse Leydig cells

182

.

Therefore, more research is needed to understand the variability and mechanism behind
the effects of BPA on StAR in the male reproductive system.

1.4.2

Female Reproductive Steroidogenesis

Due to BPA activity as an estrogen mimicking chemical, the effects of BPA on the
female reproductive system and fertility has also been investigated. Of interest is a study

45

by Ikezuki, et al. 59 that used enzyme-linked immunosorbent assays (ELISA) to determine
BPA levels of 1-2 ng/mL in 36 human follicular fluid samples. In contrast, when
measuring BPA with high-performance liquid chromatography and mass spectrometry
(HPLC-MS), no BPA was detected in the five human follicular samples examined 183.
Ovarian steroidogenesis is fundamental for estrogen production, which is essential for
ovarian function 184. In ovaries, theca cells use cholesterol to produce testosterone via the
steroidogenic pathway, which is then further converted to estrogen in granulosa cells by
the enzyme aromatase (cyp19A)

184

. The effects of BPA on estrogen, androstenedione

and DHEA have been widely reported in the literature

184

. In vitro studies have

demonstrated increased estrogen synthesis, and as shown by Peretz, et al. 185, impairment
of follicular growth. However, BPA exposure in rodent models result in inconsistent
outcomes184. Gamez, et al. 186 reported increased estradiol and FSH levels in pre-pubertal
female rats exposed to 3µg/kg/d BPA prenatally. In contrast, ovine female offspring
prenatally exposed to three different BPA doses (0.05, 0.5, or 5mg/kg bw/day) had no
changes in estradiol levels, but did have a shortened time of estradiol surge compared to
the LH surge peak, indicating potential fertility problems

187

. Epidemiological studies

have also found that higher BPA levels lead to higher serum estradiol levels in most cases
184

. However, few human studies employ healthy female subjects, tending to focus on

women attending clinics for in vitro fertilization or other reproductive conditions

184

.

Thus, the effects of BPA on ovarian steroidogenesis and function appear to be dose-,
species- and time-dependent, with more investigation necessary to provide conclusive
results.
Numerous investigators have looked at levels of the key steroidogenic protein StAR,
since it is involved in all steroid hormone production as well as being the rate-limiting
step in steroidogenesis (Table 1.3 and 1.4). BPA inhibits StAR in cultured mouse
ovarian follicles in a variety of mouse strains

185,188,189

. Conversely, BPA increases

cyp11A1 and StAR mRNA in rat ovarian theca-interstitial (T-I) cells and granulosa cells
190

. However, BPA had no effect on StAR mRNA in luteinized human granulosa cells 191.

In vitro studies showed that BPA inhibited StAR protein expression in T-I and granulosa
cells 192. In contrast, Xi, et al. 179 found no change in ovarian StAR expression with either
prenatal or postnatal BPA exposure. Thus, the effects of BPA exposure on steroidogenic
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enzymes are animal- and tissue-specific and vary depending on the type of BPA
exposure. Nevertheless, it is important to note that regulation of steroidogenesis in
reproductive tissues differs from that of the adrenal gland.

47

Table 1.3: Effects of BPA on testicular and ovarian StAR expression in vitro.
Time of
BPA

Dose

Results

Primary antral
follicles from
FVB, and
C57BL/6
Primary CD-1
mouse antral
follicles
Primary mouse
follicles from
FVB mice
Primary rat thecainterstitial and
granulosa cells

24-96 h

1-100 µg/ml

Decreases mRNA of
StAR after 72-96 h after
10-100 µg/ml BPA.

189

24-96 h

1-100 µg/ml

188

120 h

4.4-440 µM

Decreases mRNA of
StAR at 72-96 h with
10-100 µg/ml
Decreases StAR after
440 µM

72 h

10-7-10-4 M

Increases StAR mRNA
after 10-5-10-4 M in
theca cell and 10-4 M in
granulosa cells

190

Luteinized human
granulosa cells

48 h

0.02, 0.2, 2,
20 µg/ml

No effect on StAR
mRNA

191

10 µM

No effect on StAR
mRNA

182

Cell type

Primary culture of 17 h
mouse leydig
cells

Reference

185
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Table 1.4: Effects of BPA on testicular and ovarian StAR expression in vivo.
Animal
Model

Tissue

Time of
exposure

Dose and
method

Results

Reference

Swiss
Testes
albino male
mice

60 days

IP injection
Decrease StAR
of 0.5, 50 and protein at all
100 µg/kg
doses
body
weight/day

178

Wistar/ST
male rats

Testes

42 days

174

Wistar
male rats

Testes

45 days

Sprague
Dawley
male Rats

Testes

56 days

SC injections
of 20, 100, or
200 mg
BPA/kg/day
Gavaged
0.005, 0.5,
50, and 500
µg/kg bw/day
Gavaged
0.0005, 0.5, 5
mg/kg/bw

Sprague
Dawley
female rats

Ovary

90 days

SpragueDawley
rats

Fetal
testes

E11-20

ICR Mice

Offspring
adult
testes
Ovary
and
testes

E1-5

CD-1 mice

StAR mRNA and
protein decreased
with 100 and 200
mg dose
Decreased StAR
protein at all
doses

175

Increases StAR
mRNA and
protein at
5mg/kg/bw dose
Gavaged with Decrease StAR
0.001, or 0.1 protein at all
BPA mg/kg
doses
bw

177

SC injections
of 0.02, 0.5,
or 400
mg/kg/day
20 µg/kg/day
orally

180

Decreased StAR
mRNA at 400
mg/kg/day

StAR mRNA
decreased at PND
35-50
Cohort
Gavaged
Cohort A:
A: E1Cohort A:
decreased StAR
PND 49
12-50
mRNA and
Cohort B: mg/kg/day
protein at
PND 20- Cohort B: 25- 50mg/kg/day in
49
50 mg/kg/day testes, no change
in ovaries
Cohort B: no
change in StAR
mRNA

192

181

179

49

1.4.3

Adrenal Steroidogenesis

Due to the essential role of glucocorticoid in maintaining whole body homeostasis,
epidemiological studies have associated high levels of BPA with HPA dysfunction
A recent study by Giesbrecht, et al.

57

57,193

.

demonstrated that pregnant women with high

urinary BPA (1.66-43.20 ng/mL) had lower waking cortisol levels and flatter diurnal
cortisol rhythms, providing evidence for the potential of BPA to alter the HPA axis and
cortisol response in adults

57

. The offspring of the same women were examined after

parturition, to determine the effects of high BPA exposure on infant cortisol levels and
reactivity

193

. This study showed an association between high maternal BPA levels and

increased basal salivary cortisol levels in female infants, but decreased cortisol levels in
male infants compared to infants exposed to low BPA levels

193

. Additionally, cortisol

reactivity was decreased in female infants and increased in male infants exposed to high
prenatal BPA

193

. Taken together, these studies shown an association of chronic prenatal

exposure to BPA with dysfunction of the HPA-axis in humans 57,193.
The effects of BPA on plasma levels of corticosterone have been evaluated in numerous
experimental animal studies, however the effects appear to be dependent on the animal
used, dosage of BPA, timing and length of exposure, route of exposure, and time of
corticosterone measurement (Table 1.5). The sex-specificity of BPA effects on
corticosterone levels remain disputed. An increase in corticosterone levels in male but not
female adult offspring was seen in rats pre- and post-natally exposed to 2 µg/kg
subcutaneous injections of BPA from E10 to PND7

80,81

. However, an increase in

corticosterone levels was seen in female, but not male, mid-adolescence rat offspring
when pre- and post-natally exposed to 40 µg/kg BPA in orally throughout pregnancy and
lactation

194,195

. No changes in corticosterone were seen in either sex of rats at PND21

when gavaged with 2.5 or 25 µg/kg/day BPA from E6 to PND21 196.
The effects of acute BPA exposure on adrenal steroidogenic enzymes have been
demonstrated in the adrenal mouse cell line Y-1, as well as in rats acutely exposed to
BPA 197. Lan et al. 197 demonstrated that in vitro exposure to BPA levels from 50-10,000
nM was sufficient to elevate cyp11A1 protein levels in a dose-dependent manner, but did
not affect SF-1 levels

197

. Additionally, this group showed that daily subcutaneous BPA

injections of 0.5 µg/kg for three days resulted in increased plasma corticosterone and

50

adrenal cyp11A1 protein levels in male Sprague-Dawley rats 197. These studies show that
BPA alters adrenal steroidogenesis in cell and animal models; however, the effects of
prenatal BPA exposure on adrenal steroidogenesis have yet to be investigated.
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Table 1.5: Effects of BPA on basal corticosterone levels.
Animal
Model

Time of
exposure

C57BL/6

E7.5-E18.5

SpragueDawley rats

E10-PND7

SpragueDawley rats

E6-E21
prenatally,
PND1PND21
directly to
pup

SpragueDawley rats

Throughout
pregnancy
and
lactation

Wistar rats

Wistar rats

Throughout
pregnancy
and
lactation
Throughout
pregnancy
and
lactation

Dose and
Method
25 mg
BPA/kg in
food
orally
administered
2 µg/(kg/day)
of BPA
Orally
gavaged 2.5
and 25
µg/kg/day
orally
gavaged
40 µg/kg/day
of BPA
orally
administered
40 µg/kg/day
of BPA
orally
administered
40 µg/kg/day
of BPA
2µg/(kg/day)
BPA
SC injections

Basal
Age of
Corticosterone Reference
evaluation
levels
E18.5

No change

PND80

Increased in
males

PND21

No change in
either sex

PND40-50

Increased in
females

PND46

Increased in
females and not
males

PND46

Increased in
females but not
males

PND80

Increased in
males and not
females

SpragueDawley rats

E10-PND7

Deer mice

2 weeks
prior to
mating and
throughout
pregnancy
and
lactation

50mg of
BPA/kg feed
weight

PND90

No changes in
males

3 days

0.5µg/kg BW
BPA
SC injections

8 weeks

Increased in
males

SpragueDawley rats

68

81

196

198

195

194

80

199

197

52

1.5

Rationale

BPA as an EDC in numerous tissues is well established

2,10,15

. Moreover, the potential

adverse effects of in utero BPA exposure on fetal development and the long-term
consequences of this exposure is of great concern

2,6,13

. Indeed, prenatal BPA exposure

has a wide range of adverse health effects, including reproductive
200,201

, respiratory

neurological

11

68,202

, immunological

203,204

, metabolic

179-181

66,67,205

, cardiovascular

, behavioral and

disorders, in both the fetus and adult offspring. Thus, brief exposure to

BPA during critical periods of development can have lifelong health consequences.
The adrenal gland plays a critical role in production of glucocorticoids which are
necessary in maintaining whole body homeostasis. Furthermore, the adrenal gland is
highly vulnerable to environmental toxin insult due in part to its potential for free radical
generation during steroidogenesis, ability to take up lipophilic agents, high vascularity
allowing delivery of toxins, and high levels of CYP enzymes available to activate toxins
206,207

. Given the above, my thesis focuses on the long-term effects of prenatal BPA

exposure on adrenal gland development and steroidogenic function in adulthood.
Prenatal BPA exposure has been shown to increase plasma glucocorticoid levels in
offspring, in a sex-specific manner. However, the precise nature of these sex-specific
effects on plasma corticosterone levels remains obscure

80,194,195,198

. Moreover, whether

the BPA-induced increases in plasma corticosterone levels are a result of enhanced
adrenal steroidogenesis is not known. Importantly, whether prenatal BPA exposure alters
adrenal development remains to be demonstrated. Therefore, this thesis addresses these
important questions.

1.6

Hypothesis

I hypothesize that prenatal exposure to BPA disrupts adrenal gland development and
steroidogenic function in adult mouse offspring.

1.7
i.

Objectives

To determine the effects of prenatal BPA exposure on adrenal gland development,
and adrenal steroidogenic function in vivo.
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ii.

To determine the molecular mechanisms that underlie the BPA-induced aberrant
adrenal gene expression in vitro.

iii.

To determine the molecular mechanisms underlying the BPA-induced aberrant
adrenal gland development in vitro.

1.8
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1

PRENATAL EXPOSURE TO BISPHENOL A DISRUPTS
STEROIDOGENESIS IN ADULT MOUSE
OFFSPRING1

Reproduced (adapted) from: Medwid S, Guan H, Yang K (2016) Prenatal exposure to
bisphenol A disrupts steroidogenesis in adult mouse offspring. Environ Toxicol
Pharmacol. 43: 203-8
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2.1 Introduction
Bisphenol A (BPA) is a ubiquitous endocrine disrupting chemical, being present in
polycarbonate plastics, epoxy resins, paper receipts, and cardboards, as well as water and
air samples

1-3

. Of foremost concern is exposure to BPA during the critical period of

organ maturation 4. Indeed, BPA has been detected in placental tissues and fetal blood,
demonstrating BPA’s ability to cross the placenta and reach the fetus

3,5

. Numerous

human epidemiological studies have demonstrated an association between gestational
exposure to BPA and pregnancy complications, male genital abnormalities, childhood
obesity, childhood asthma and altered neurological development in children

6

.

Furthermore, in vivo animal studies have shown that developmental BPA exposure results
in a wide range of adverse effects, including reproductive, cardiovascular,
immunological, metabolic, behavioural, and neurological disorders as well as certain
cancers in adult offspring. In addition, many of these adverse effects are sex specific 3,4,7.
Due to the critical role of glucocorticoids (cortisol in humans, and corticosterone in
rodents) in maintaining whole body homeostasis, the effects of BPA on the
hypothalamic-pituitary-adrenal axis had been examined previously. It was found that
maternal exposure to BPA during pregnancy and lactation resulted in increased basal
corticosterone levels in juvenile female, but not male rats

8-10

. Furthermore, perinatal

BPA exposure led to abnormal adrenal cortex structure, including increased adrenal gland
weight in females, accompanied by a reduction in the zona reticularis and hyperplasia of
the zona fasciculata in both sexes 8. In contrast, Chen, et al. 11 reported that prenatal BPA
exposure resulted in increased corticosterone levels in adult male rats only. Thus, the
precise nature of these sex-specific effects of developmental exposure to BPA on
circulating corticosterone levels remains obscure. Importantly, whether the BPA-induced
increases in circulating corticosterone levels are a result of enhanced adrenal
steroidogenesis is unknown. Therefore, the present study was undertaken to address these
two important questions.
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2.2
2.2.1

Materials and Methods
Animal Experiments

The use of animals in this study was approved by the Council on Animal Care at the
University of Western Ontario, following the guidelines of the Canadian Council on
Animal Care. Breeding pairs of adult C57BL/6 mice were purchased from Charles River
Laboratories (Wilmington, MA). To minimize environmental BPA exposure, mice were
housed in polypropylene cages with glass water bottles. Mice were allowed food and
water ad libitum, and maintained in humidity and temperature-controlled rooms on a
12 h/12 h light-dark cycle. Female mice were placed overnight with males, and detection
of vaginal plug the next morning indicated pregnancy, and marked as embryonic day 0.5
(E0.5). Pregnant dams were fed either a control diet (phytoestrogen-free food pellets
supplemented with 7% corn oil; TD.120465, Harlan Teklad, Madison, WI) or the control
diet supplemented with 25 mg BPA/kg feed weight (equivalent to 5 mg BPA/kg body
weight; TD.120466, Harlan Teklad, Madison, WI) from E7.5 to postnatal day (PND) 0.5.
The gestational age of E7.5 was chosen as the start of the feeding regime in order to
avoid any confounding effects of BPA on embryo implantation. After birth, both controland BPA-fed dams were switched to regular chow for remainder of the study. Pups were
weaned on PND 21, separated by sex and fed regular chow. Five litters of control and
BPA were used, with number of pups between 6 and 11 pups per litter. Litters were
culled at 5 pups per sex per litter. They were group housed by litter, experimental
treatment and sex. Offspring were sacrificed between 8 and 10 weeks of age using carbon
dioxide asphyxiation. Blood samples were collected via cardiac puncture in heparinized
capillary tubes (Fisher brand Cat. No. 22-260-950), and centrifuged at 2000g for 10 min
at 4 °C. Plasma was then harvested were stored at −80 °C. Adrenal glands were dissected,
weighed, snap-frozen in liquid nitrogen, and stored at −80 °C. All sacrifices and sample
collection were done between 9:00–11:00 am.

2.2.2

Western Blot Analysis

Due to the limited tissue quantity (i.e., the tiny size of mouse adrenal glands), we made a
strategic decision to determine changes in protein, rather than mRNA, abundance
following exposure to BPA during critical periods of adrenal gland development. This is
because information on alterations in protein levels is more biological meaningful.
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Furthermore, the limited tissue availability also precluded the possibility of conducting
enzyme activity assays, which would require greater amounts of tissues in comparison to
western blot analysis.
Levels of various proteins were analyzed using standard western blot analysis, as
previously described

12

. Briefly, sodium phosphate buffer, (pH 7.0), was used at a 10

times volume dilution to hand homogenize 2–3 adrenals gland from the same sex and the
same litter before being mixed with equal amounts of SDS gel loading buffer (50 mM
Tris-HCL, pH 6.8, 2% wt/vol SDS, 10% vol/vol glycerol, 100 mM DTT and 0.1% wt/vol
bromophenol blue) to be loaded to a standard 10% SDS-PAGE gel. Protein was then
transferred to a PVDF transfer membrane (Amersham Hybond-P, Cat. No. RPN303F, GE
Healthcare Lifesciences, Baie D'Urfe, QC), and blocked overnight with 5% milk in TTBS
(0.1% vol/vol Tween-20 in TBS) to decrease non-specific antibody binding. Membranes
were then probed with primary antibodies (Table 2.1) for 1–2 h at room temperature.
Washing was done with TTBS, 3 × 10 min before labeling with horseradish peroxidaselabeled rabbit secondary antibody (Table 2.1), for 1 h at room temperature. After
3 × 10 min TTBS washes, proteins were detected using ECL and visualized using a
chemiliminescence (Cat. No. WBLUR0500, Luminata Crescendo, Western HRP
Substrate; Millipore, Etobicoke, ON) and captured on the VersaDoc Imaging System
(BioRad, UK). Densitometry was performed using Image Lab Software, comparing
levels of proteins expressed as percent of controls.
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Table 2.1: Primary and secondary antibodies used for western blotting.
Antibody

Company

Catalog Number

Dilution Used

Perilipin

Cell Signaling

3470

1:1000

StAR

Santa Cruz

Sc-25806

1:4000

Cyp11A1

Bioss

Bs-3608R

1:200

SF-1

Abcam

Ab168380

1:1000

GAPDH

Imgenex

IMG-5567

1:10000

Anti-Rabbit

R&D systems

HAF008

1:3000
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2.2.3

Hormone Assays

Levels of corticosterone and ACTH in plasma samples (plasma from one litter and the
same sex were pooled, and used as one sample) were determined with an ELISA Kit
following the manufacturer’s instructions (corticosterone: Abcam, ab108821, 1:60
plasma dilution, Toronto, ON; ACTH: Phoenix Peptide EKE-001-21, 1:1 plasma dilution,
Burlingame, CA). To eliminate inter-assay variations, all samples were analyzed in
triplicate in one assay, and the intra-assay coefficient of variation was <5%.

2.2.4

Statistical Analysis

Results are presented as mean ± SEM of four to five different litters, as indicated in
figure legends. Data were analyzed using two-way ANOVA followed by Tukey’s posthoc test, or Student’s t-test as indicated. Significance was set at p < 0.05. Calculations
were performed using Graphpad Software Prism version 6.

2.3
2.3.1

Results
Effects of prenatal BPA exposure on adrenal gland weight

To determine if prenatal BPA exposure affected body weight, mice were weighed at 8
weeks. No significant differences in body weight were observed in either sex of BPAexposed and non-exposed control mice (Figure 2.1A & B). To investigate if prenatal
BPA exposure resulted in altered adrenal gland weight, the weight of adrenal glands and
the ratio of adrenal gland weight to body weight were determined. An increase in adrenal
gland weight was observed in both male (P < 0.05) and female (P < 0.01) mice prenatally
exposed to BPA when compared with controls (Figure 2.1C & D). Furthermore, the ratio
of adrenal gland weight to body weight was significantly increased in both BPA-exposed
male (P < 0.05) and female (P < 0.01) mice (Figure 2.1E & F).
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Figure 2.1: Effects of prenatal BPA exposure on adrenal gland weight.
Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the control diet
supplemented with 25 mg BPA/kg food pellets from E7.5 to birth. At eight weeks of age,
offspring were sacrificed, body weight (A & B) and adrenal gland weight (C & D) were
recorded, and adrenal gland to body weight ratio (E & F) was then calculated. Data are
presented as mean ± SEM (n = 16–22; *P < 0.05, **P < 0.01, vs. control).
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2.3.2

Effects of prenatal BPA exposure on basal plasma
corticosterone and ACTH levels

To determine if prenatal BPA exposure affected adrenal plasma corticosterone, plasma
corticosterone levels were measured using ELISA. We found that corticosterone levels
were significantly increased in both male (P < 0.01) and female (P < 0.05) mice
prenatally exposed to BPA when compared to control mice (Figure 2.2A). To ascertain if
elevated corticosterone levels were a result of hyper-pituitary activity, plasma ACTH
levels were measured with ELISA. We observed no differences in plasma ACTH levels
between control and prenatally BPA-exposed mice (Figure 2.2B).

80

Corticosterone
(ng/ml)

1000

***

***

750

**

B

*

500
250
0

C

BPA
Male

C BPA
Female

ACTH (ng/ml)

A

1.5
1.0
0.5
0.0

C

BPA
Male

C

BPA

Female

Figure 2.2: Effects of prenatal BPA exposure on plasma corticosterone and ACTH
levels.
Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the control diet
supplemented with 25 mg BPA/kg food pellets from E7.5 to birth. At eight weeks of age,
offspring were sacrificed, and plasma samples were collected. Plasma levels of
corticosterone (A) and ACTH (B) were measured by standard ELISA. Data are presented
as mean ± SEM; statistical significance was determined using a 2-way ANOVA followed
by Tukey’s post-hoc test (n = 3–5; *P < 0.05, **P < 0.01, ***P < 0.001).
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2.3.3

Effects of prenatal BPA exposure on perilipin protein levels

To determine if prenatal exposure to BPA altered substrate availability for adrenal
steroidogenesis, adrenal levels of perilipin, a surrogate for cholesterol content

13

, were

measured using western blot analysis. The level of perilipin protein was similar between
control and prenatally BPA-exposed mice in both sexes (Figure 2.3).
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Figure 2.3: Effects of prenatal BPA exposure on perilipin protein levels in adrenal
glands.
Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the control diet
supplemented with 25 mg BPA/kg food pellets from E7.5 to birth. At eight weeks of age,
offspring were sacrificed, and adrenal glands were collected. Levels of perilipin protein
in adrenal gland tissue homogenates were determined separately in males (A & C) and
females (B & D) by western blot analysis. Data are presented as mean ± SEM (n = 4).
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2.3.4

Effects of prenatal BPA exposure on StAR and cyp11A1
protein levels

To study the effects of prenatal exposure to BPA on the rate-limiting steps of
steroidogenesis, levels of StAR and cyp11A1 proteins were measured by western
blotting. We found a significant increase in both StAR (P < 0.01) and cyp11A1 (P < 0.05)
protein levels in prenatally BPA exposed female mice compared to controls (Figure
2.4B, D & F). By contrast, no changes in either StAR or cyp11A1 protein were observed
in male mice prenatally exposed to BPA when compared to control males (Figure 2.4A,
C & E).
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Figure 2.4: Effects of prenatal BPA exposure on StAR and Cyp11A1 protein levels.
Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the control diet
supplemented with 25 mg BPA/kg food pellets from E7.5 to birth. At eight weeks of age,
offspring were sacrificed, and adrenal glands were collected. Levels of StAR and
cyp11A1 protein in adrenal gland tissue homogenates were determined separately in
males (A, C & E) and females (B, D, & F) by western blot analysis. Data are presented as
mean ± SEM (n = 4; *P < 0.05, **P < 0.01 vs. control).
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2.3.5

Effects of prenatal BPA exposure on SF-1 protein levels

To investigate the effects of prenatal exposure to BPA on the regulatory mechanisms of
adrenal steroidogenesis, we examined the expression of steroidogenic factor-1 (SF-1), a
key transcription factor involved in the regulation of StAR and cyp11A1. We found no
significant changes in the level of SF-1 protein in either female or male mice prenatally
exposed to BPA when compared to control mice of the same sex (Figure 2.5).
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Figure 2.5: Effects of prenatal BPA exposure on SF-1 protein levels in adrenal
glands.
Pregnant mice were fed a control diet (phytoestrogen free food pellets) or the control diet
supplemented with 25 mg BPA/kg food pellets from E7.5 to birth. At eight weeks of age,
offspring were sacrificed, and adrenal glands were collected. Levels of SF-1 protein in
adrenal gland tissue homogenates were determined separately in males (A & C) and
females (B & D) by western blot analysis. Data are presented as mean ± SEM (n = 4).
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2.4

Discussion

In the present study, we demonstrate that prenatal exposure to BPA results in increased
basal corticosterone levels independent of circulating ACTH levels in both male and
female adult mouse offspring. Furthermore, we provide evidence indicating that BPAinduced increases in basal corticosterone levels are likely a consequence of up-regulated
adrenal steroidogenesis in female mice while the mechanisms behind the BPA-induced
increase in corticosterone levels in males are unknown. Thus, our present findings
provide novel insight into the long-term and sex-specific effects of developmental BPA
exposure on adrenal steroidogenesis.
The dose of BPA used in this study (25 mg BPA/kg diet; equivalent to 5 mg BPA/kg
body weight) was chosen based on our previous dose-response studies in which we found
that prenatal exposure to this dose of BPA led to impaired fetal lung maturation without
any effect on fetal body weight or litter size

14

. This dose is also one tenth of the no

observed adverse effect level (NOAEL) for rodents (50 mg/kg/day), as determined by the
U.S.

Environmental

Protection

Agency

(IRIS

2012).

Importantly,

maternal

concentrations of BPA in our mouse model were determined to be 1.7 ng/ml measured
using gas chromatography–mass spectrometry (GC–MS) 14, which is at the lower end of
the range of those reported in the serum of pregnant women in the US 15.
As a first step in investigating the effects of prenatal BPA exposure on adrenal gland
development and function, we sought to determine changes in adrenal gland weight. We
found that the weight of adrenal glands was significantly increased in both male and
female mice prenatally exposed to BPA when compared to offspring of control mice.
Since BPA did not alter body weight, we observed a similar increase in the ratio of
adrenal gland weight to body weight in prenatally BPA-exposed offspring in both sexes.
This is in marked contrast to the findings of a previous study, which showed that
maternal BPA exposure during pregnancy and lactation led to increases in both adrenal
gland weight and the ratio of adrenal to body weight only in female but not male juvenile
rats 8. Although the precise reasons for the discrepancy between the two studies are not
clear, it is possible that differences in the dosage of BPA and the length of its exposure as
well as the animal species and the offspring age (at which the study was conducted) are

88

important contributing factors. Increased adrenal weight can result in increased adrenal
steroid output, which can be a result of increased output per adrenal cell and/or an
increase in the number of adrenal cells.
We then determined the functional significance of the BPA-induced increases in adrenal
gland weight by examining changes in plasma levels of corticosterone, the principal
glucocorticoid synthesized by the adrenal gland in rodents. We found that although
prenatal exposure to BPA resulted in a significant increase in basal corticosterone levels
in both male and female mice, this increase was greater in BPA exposed males compared
to BPA females. This suggests that plasma corticosterone levels are more vulnerable to
BPA exposure in utero in male than in female offspring. Previous studies reported sexdependent changes in plasma corticosterone resulting from developmental exposure to
BPA. For example, one study showed that prandial administration of 40 µg BPA/kg body
weight per day throughout pregnancy and lactation led to elevated plasma corticosterone
levels in juvenile female and but not male rats

8,9

. In another study, Zhou, et al.

10

also

observed an increase in basal corticosterone in female juvenile rats exposed to 40 µg
BPA/kg body weight per day throughout pregnancy and lactation; however male rats
were not examined in that study. In contrast, Chen, et al.

11

reported an increase in

corticosterone levels in adult male but not female rats as a result of daily subcutaneous
administration of 2 µg BPA/kg body weight from gestation day 10 to lactation day 7.
These discrepancies can be attributed to differences in the study design, including the
dosage, the timing, the duration, and the mode of BPA administration as well as the age
at which corticosterone levels were measured. Consistent with previous studies, there
were no differences in basal corticosterone levels between control male and female adult
mice

16-18

. It is interesting to note that basal corticosterone levels were slightly higher in

both males and females in our study when compared to those published previously

19-21

,

which may be attributed to differences in the time of the day when blood samples were
collected, because corticosterone is known to be released in a circadian fashion

22,23

.

Furthermore, the presence of varying degrees of potential stressors in the animal housing
environment, such as noise, human traffic and lighting conditions, may also be a
contributing factor 24-26.
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Given that elevated circulating corticosterone levels are commonly associated with
enhanced ACTH release from the anterior pituitary 27, we measured plasma ACTH levels
and found that they were not altered in either female or male offspring following prenatal
BPA exposure. This suggested that the BPA-induced increases in basal plasma
corticosterone levels are independent of pituitary ACTH, and likely the result of a direct
effect of BPA on the adrenal gland. Our present findings are in marked contrast with
those reported previously showing a concomitant increase in plasma levels of
corticosterone and ACTH in adult male rats

11

and juvenile female rats following

10

perinatal exposure to BPA . As discussed above, differences in the timing, dosage and
duration of BPA exposure likely accounted for the contrasting findings between these
studies.
Our conclusion of BPA exerting a direct effect on the adrenal gland is supported by
previously published in vitro evidence showing that BPA inhibited cortisol and
corticosterone secretion in human adenocarcinoma H295R cells, by inhibiting cyp17A1
(17,20 lyase) 28. Furthermore, BPA reduced the mRNA levels of StAR and cyp11A1, the
two rate-limiting factors in the de novo steroidogenesis, in cultured mouse ovarian
follicles

29,30

, while another study reported increased mRNA levels in rat ovarian theca-

interstitial (T-I) cells and granulosa cells following exposure to BPA

31

. Furthermore,

BPA has been shown to alter mRNA levels of other steroidogenic P450 enzymes, such as
3β-HSD and 17β-HSD in rat testis

32

. In addition, BPA inhibited the activities of 3β-

HSD, CYP17A1 and 17β-HSD3 in both human and rat testis microsomes 33. However, to
date, changes in the expression of StAR and cyp11A1, or any other proteins/enzymes
involved in steroidogenesis, in the adrenal gland following BPA exposure in vivo have
not been examined.
As a first step in examining the effects of prenatal exposure to BPA on steroidogenesis in
the adrenal gland, we sought changes in substrate availability by determining and
comparing levels of perilipin protein between control and BPA exposed offspring.
Perilipin is a protective coating protein surrounding the periphery of lipid droplets, which
are stored in the adrenal gland and are associated with cholesterol ester droplets 13,34. We
found that perilipin protein content was not different between control and BPA exposed
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mice in either sex, suggesting that cholesterol content, and by inference the substrate
availability for steroidogenesis, is not altered in adult mouse offspring prenatally exposed
to BPA. This is similar to the findings of a previous in vitro study, which showed that
BPA had no effect on perilipin levels in human hepatocyte cells

35

. To the best of our

knowledge, this is the first study to examine changes in perilipin expression following
BPA exposure in vivo.
We then examined changes in StAR and cyp11A1, the two rate-limiting steps in
steroidogenesis. We found that adrenal protein levels of both StAR and cyp11A1 were
elevated in female but not male mice, suggesting that the BPA-induced increases in
corticosterone levels in our female offspring are likely the result of an enhanced adrenal
steroidogenesis. Importantly, these findings demonstrate that although prenatal exposure
to BPA alters basal plasma corticosterone levels in both male and female offspring, its
effects on adrenal steroidogenesis are sex-specific. A similar sex-dependent effect was
reported by Xi, et al.

36

, who showed that developmental exposure to BPA led to

decreased expression of StAR and cyp11A1 in the testes, whereas no changes in StAR
and an increase in cyp11A1 were detected in the ovaries. However, the lack of a
corresponding increase in StAR and cyp11A1 in the adrenal gland of the male offspring
begs the question of the reasons behind increased corticosterone levels in these animals.
Potential mechanisms/reasons may include changes in one or more of the steroidogenic
enzymes downstream of cyp11A1. Obviously, future studies will be required to address
this issue.
Given that steroidogenic factor-1 (SF-1) is a key transcription factor responsible for the
induction of StAR and cyp11A1 as well as other steroidogenic enzymes

37,38

, we

determined if changes in the expression of this transcription factor are responsible for our
observed increases in levels of StAR and cyp11A1 proteins in the adrenal gland of BPAexposed female offspring. We found that adrenal levels of SF-1 protein were similar
between control and BPA-exposed mice in both males and females. This suggested that
other transcription factors, such as C/EBPs, Sp1, and DAX1 39,40, may be involved in upregulating StAR and cyp11A1 in the adrenal gland of our BPA-exposed female offspring.
Alternatively, BPA-induced phosphorylation of SF-1 could account for the increased
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level of StAR and cyp11A1 protein, since phosphorylation of SF-1 at the StAR promoter
is required to increase expression of StAR 41,42. Obviously, future studies will be required
to examine these possibilities. It is interesting to note that BPA exposure resulted in
decreased expression of SF-1 in cultured human granulosa cells 43.

2.5

Conclusion

In conclusion, the present study demonstrates that prenatal exposure to BPA disrupts
corticosterone homeostasis in the circulation without altering plasma ACTH levels in
both male and female adult mouse offspring. We also provide evidence that BPA disrupts
steroidogenesis independent of SF-1 in a sex-specific manner. Thus, our present findings
provide novel insight into the dynamic effects of developmental exposure to BPA on the
pituitary-adrenal axis development and function.

2.6
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3

1

BISPHENOL A INDUCES STEROIDOGENIC ACUTE
REGULATORY PROTEIN (StAR) EXPRESSION VIA
AN UNKNOWN MECHANISM INDEPENDENT OF
TRANSCRIPTION, TRANSLATION AND PROTEIN
HALF-LIFE IN HUMAN ADRENAL CORTICAL CELLS1

The material in this chapter is based on a manuscript submitted to Steroids: Medwid S,
Guan H, Yang K. Bisphenol A induces steroidogenic acute regulatory protein (StAR)
expression via an unknown mechanism independent of transcription, translation and
protein half-life in human adrenal cortical cells (2017).
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3.1

Introduction

In Chapter 2, I demonstrated that prenatal BPA exposure increased StAR protein
expression in adult female offspring. Given that StAR is the rate-limiting step in adrenal
steroidogenesis, in the following chapter, I sought to determine the molecular
mechanisms underlying BPA-induced StAR expression using an in vitro cell model
system
Bisphenol A (BPA) is a widespread endocrine disrupting chemical, and a source of major
health concerns. BPA is commonly used in polycarbonate plastics and epoxy resins, such
as plastic containers and the inner-lining of food cans 1-5. BPA is present in human saliva,
urine, and plasma. More concerning is the presence of BPA in placenta, cord blood,
amniotic fluid and breast milk

6-9

, raising serious concerns about exposure to BPA in

utero and during critical periods of postnatal development

10

. Indeed, numerous human

epidemiological studies have demonstrated an association between gestational exposure
to BPA and adverse health outcomes including pregnancy complications, male genital
abnormalities, childhood obesity, childhood asthma and altered neurological development
in children and adults 11-13.
We recently showed that prenatal BPA exposure led to altered adrenal gland development
and function in adult mouse offspring

14

. Specifically, plasma levels of corticosterone

were elevated concomitant with increased adrenal levels of steroidogenic acute regulatory
protein (StAR), the rate-limiting step in steroidogenesis, in adult female offspring

14

.

StAR is responsible for the transport of free cholesterol from the outer mitochondrial
membrane (OMM) to the inner mitochondria membrane (IMM), the first and the ratelimiting step in steroidogenesis 15. BPA is known to alter StAR mRNA and protein levels
in various reproductive tissues, and these effects appear to be species-, sex-, dose- and
exposure time-specific

16-27

. However, the molecular mechanisms underlying the effects

of BPA on steroidogenesis, and particularly StAR expression are largely unknown.
Therefore, the present study was designed to address this important question using a
human adrenal cortical cell line as an in vitro model system.
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3.2
3.2.1

Methods
Reagents

Bisphenol A was purchased from Sigma-Aldrich Canada Ltd. (>99% purity; CAS 80-057; Oakville, ON) and dissolved in ethanol to prepare a 10mM stock solution, and stored
at -20°C. ICI 182, 760 (ICI) was purchased from Tocris (cat. no. 1047) and dissolved in
DMSO to prepare a 100mM stock, and stored at -20°C. 4,4',4''-(4-Propyl-[1H]-pyrazole1,3,5-triyl)trisphenol) (PPT) and 2,3-bis(4-Hydroxyphenyl)-propionitrile (DPN) were
purchased from Tocris (cat. no. 1426 and 1494, respectively) and dissolved in ethanol to
a concentration of 5 mM and 100 mM, respectively, and stored at -20°C. Cycloheximide
(CHX) was purchased from Sigma (C-0934) and dissolved in ethanol to prepare a 100
mM stock and stored at -20°C.

3.2.2

Cell Culture

The adrenocortical human cell line NCI-H295 cell line was derived from an adrenal
tumor of a 48-year-old female and was first described by Gazdar et al. 28. The NCI-H295
cell line expresses all steroidogenic enzymes present in the human fetal adrenal glands
and is an established model to study adrenal steroidogenesis 29. The subline, NCI-H295A,
was further derived and characterized from the H295R cell line, and is currently the best
available model of human fetal adrenal gland cells 30. H295A cells (generously provided
by Dr. Walter L. Miller) were cultured in RPMI 1640 media (Invitrogen) with 2% fetal
bovine serum (FBS; Sigma), 0.1% insulin-transferrin-selenium supplement (Sigma
I18884) and 100IU penicillin and 100µg/mL streptomycin (Invitrogen) at 37°C (5%
CO2). Growth medium was replaced every other day.

3.2.3

Western Blot Analysis

Levels of various proteins were analyzed using standard western blot analysis, as
previously described 31. Briefly, cells were lysed in SDS gel loading buffer (50 mM TrisHCL, pH 6.8, 2% wt/vol SDS, 10% vol/vol glycerol, 100 mM DTT and 0.1% wt/vol
bromophenol blue) to be loaded in a standard SDS-PAGE gel. Protein was then
transferred to a PVDF transfer membrane (Amersham Hybond-P, cat. no. RPN303F, GE
Healthcare Lifesciences, Baie D'Urfe, QC), and blocked overnight with 5% milk in TTBS
(0.1% vol/vol Tween-20 in TBS). Membranes were then probed with primary antibodies
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for 1-2 hours at room temperature (Table 3.1). Washing was done with TTBS, 3×10
minutes before labeling with horseradish peroxidase-labeled secondary antibody (Table
3.1) for 1 hour at room temperature. After 3×10 minute TTBS washes, proteins were
detected using ECL and visualized using chemiluminescence (cat. no. WBLUR0500,
Luminata Crescendo, Western HRP Substrate; Millipore, Etobicoke, ON) and captured
on the VersaDoc Imaging System (BioRad). Densitometry was performed using Image
Lab Software, comparing levels of proteins expressed as percent of controls.
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Table 3.1: Primary and secondary antibodies used for western blotting.
Antibody

Company

Catalog Number

Dilution Used

StAR

Santa Cruz

Sc-25806

1:4000

GAPDH

Cell Signaling

14C10

1:10000

Cyp11A1

Bioss

Bs-3608R

1:200

3β-HSD

Santa Cruz

Sc-30820

1:500

ERα

Santa Cruz

Sc-543

1:500

ERβ

Santa Cruz

Sc-8974

1:1000

SF-1

Abcam

Ab168380

1:1000

C/EBPβ

Snata Cruz

Sc-150

1:500

Sp1

Millipore

17-601

1:8000

AKAP149

Santa Cruz

Sc-377450

1:100

β-tubulin

Imgenex

IMG-5810A

1:1000

Anti-Rabbit

R&D systems

HAF008

1:3000

Anti-goat

Millipore

AP180P

1:8000

Anti-mouse

BIO RAD

170-6516

1:7500
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3.2.4

Real time quantitative RT-PCR

The relative abundance of various mRNAs was determined by a two-step real time
quantitative RT-PCR (qRT-PCR), as described previously

32

, with the following

modifications. Briefly, total RNA was extracted from cells using RNeasy Mini Kit
(Qiagen Inc., Mississauga, ON) coupled with on-column DNase digestion with the
RNase-free DNase Set (Qiagen) according to the manufacturer’s instructions. One
microgram of total RNA was reverse-transcribed in a total volume of 20 µl using the
High Capacity cDNA Archive Kit (Applied Biosystems, Forest City, CA) following the
manufacturer’s instructions. For every RT reaction set, one RNA sample was set up
without reverse-transcriptase enzyme to provide a negative control. Gene transcript levels
of GAPDH (housekeeping gene whose expression level was found to be stable across
all treatment groups), and StAR were quantified separately by pre-designed and validated
TaqMan® Gene Expression Assays (Applied Biosystems; GAPDH Hs02758991_g1;
StAR Hs00986559_g1) following the manufacturer’s instructions. Briefly, gene
expression assays were performed with the TaqMan® Gene Expression Master Mix
(Applied Biosystems P/N #4369016) and the universal thermal cycling condition (2 min
at 50 °C and 10 min at 95 °C, followed by 40 cycles of 15 s at 95 °C and 1 min at 60 °C)
on the ViiA™ 7 Real-Time PCR System (Applied Biosystems).
The relative amount of StAR and GAPDH mRNA was quantified by the comparative
CT method (also known as ΔΔ CT method) using the Applied Biosystems relative
quantitation and analysis software according to the manufacturer’s instructions. The
amount of StAR mRNA was normalized to GAPDH (housekeeping gene) for each
treatment group. StAR mRNA in BPA treatment is expressed relative to the amount of
transcript present in the control.

3.2.5

Statistical Analysis

Results are presented as group means ± SEM for each treatment group, as indicated.
Control and BPA groups were compared using a Student’s t-test or a one-way ANOVA,
followed by a Tukey’s post hoc; statistical significance was set at P<0.05. Statistical
analysis was performed using statistical software PRISM 1992-2008 GraphPAD
Software.
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3.3
3.3.1

Results
Concentration-dependent effects of BPA on StAR protein
expression

To validate this in vitro model system, we determined the effects of various
concentrations of BPA on StAR protein levels in H295A cells. We found that treatment
with increasing concentrations of BPA (1-1000 nM) for 48 h resulted in a concentrationdependent increase in StAR protein levels (Figure 3.1).
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Figure 3.1: Concentration-dependent effects of BPA on StAR protein expression.
H295A cells were treated with various concentrations of BPA (1 – 10000 nM) for 48 h.
At the end of treatment, levels of StAR protein were determined by western blotting.
Data are presented as means ± SEM (**P<0.01, ***P<0.001; n=4 independent
experiments).
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3.3.2

Effects of BPA on selected key steroidogenic enzymes

To assess the effects of BPA on adrenal steroidogenesis, protein levels of the two key
steroidogenic enzymes, Cyp11A1 and 3β-HSD, were measured following treatment with
10 nM BPA. We showed that protein levels of both Cyp11A1 and 3β-HSD were not
different between cells treated with and without BPA (Figure 3.2A & B).
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Figure 3.2: Effects of BPA on selected key steroidogenic enzymes.
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, protein
levels of Cyp11A1 (A) and 3b-HSD (B) were measured by western blotting. Data are
presented as means ± SEM (n=4 independent experiments).
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3.3.3

Effects of BPA on ERα and β protein expression

To determine the effects of BPA on ER expression, protein levels of ERα and ERβ were
assessed following BPA treatment. We found that neither ERα (Figure 3.3A) nor ERβ
(Figure 3.3B) protein levels were altered by BPA.
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Figure 3.3: Effects of BPA on ERα and β protein expression.
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, protein
levels of ERa (A), and ERb (B) were measured by western blotting. Data are presented
as means ± SEM (n=4 independent experiments).
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3.3.4

Effects of ER agonists and antagonist on StAR protein
expression

BPA has been shown to activate both ERα and ERβ 33-35. As a first step in determining if
ER is involved in mediating the effects of BPA on StAR expression, we assessed changes
in StAR expression following treatment with the ERα selective agonist PPT and the ERβ
selective agonist DPN, respectively (Figure 3.4A). We found that both PPT and DPN
increased StAR protein levels. We then examined the effects of the ER antagonist ICI
182, 780 (ICI) on BPA-induced expression of StAR. We showed that ICI completely
prevented BPA-induced increases in levels of StAR protein (Figure 3.4B).

109

A

StAR

GAPDH

StAR/GAPDH
(%control)

200
150

*

*

*

100
50
0

Control BPA PPT DPN

B

StAR/GAPDH
(%control)

StAR
GAPDH
200

**

150
100
50
0

Control ICI

BPAICI+BPA

Figure 3.4: Effects of ER agonists and antagonist on StAR protein expression.
H295A cells were treated with 10 nM PPT, 10 nM DPN, 10 nM BPA, 100 nM ICI
182,780 (ICI), or BPA plus ICI for 48 h. At the end of treatment, levels of StAR protein
were measured by western blotting (A&B). Data are presented as means ± SEM
(*P<0.05, **P<0.01; n=5 independent experiments).
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3.3.5

Effects of BPA on key StAR transcription factors and StAR
mRNA levels

To explore the molecular mechanisms underlying BPA-induced StAR protein expression,
we determined the effects of BPA on the expression of key StAR transcription factors
15,36

and StAR mRNA. Although BPA did not alter SF-1 protein levels (Figure 3.5A), it

increased protein levels of C/EBPβ (Figure 3.5B) and Sp1 (Figure 3.5C). Interestingly,
BPA had no effect on StAR mRNA (Figure 3.5D).
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Figure 3.5: Effects of BPA on key StAR transcription factors and StAR mRNA
levels.
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, protein
levels of SF-1 (A), C/EBPβ (B) and Sp-1 (C) as well as levels of StAR mRNA (D) levels
were measured by western blotting and qRT-PCR, respectively. Data are presented as
means ± SEM (**P<0.01; n=4 independent experiments).

112

3.3.6

Effects of BPA on key StAR translation protein and StAR
pre-protein

We then investigated the possibility that BPA may influence the translation of StAR
protein by examining changes in the key kinase involved in recruiting StAR mRNA and
translating it, namely A-Kinase anchoring protein (AKAP) 149 37,38 as well as the 37-kDa
StAR pre-protein 39. Treatment with BPA did not alter levels of either AKAP149 protein
(Figure 3.6A) or 37-kDa StAR pre-protein (Figure 3.6B).
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Figure 3.6: Effects of BPA on key StAR translation protein and StAR pre-protein.
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, levels of
AKAP149 protein (A) and 37-kDa StAR pre-protein (B) were measured by western
blotting. Data are presented as means ± SEM (n=4 independent experiments).
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3.3.7

Effects of BPA on half-life of StAR protein

To determine if BPA alters the half-life of StAR protein, cells were treated with BPA for
48 h, followed by co-treatment with the translation inhibitor cycloheximide (CHX) for 2
and 4 hours prior to harvesting for StAR protein measurement. We found that BPA did
not affect the half-life of StAR protein (Control=3.1 h; BPA=3.0 h; Figure 3.7).

115

Figure 3.7: Effects of BPA on half-life of StAR protein.
H295A cells were treated with 10 nM of BPA for 48 h, and then 10 µM cycloheximide
(CHX) was added for 2 h and 4 h prior to harvest. StAR protein levels were measured by
western blotting, and its half-life determined by standard method. Data are presented as
means ± SEM (n=4 independent experiments).
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3.4

Discussion

Adrenal steroidogenesis and most notably glucocorticoid production is critically
controlled by the rate-limiting protein StAR 15,40. We recently demonstrated that prenatal
exposure to BPA resulted in altered adrenal development and function leading to
increased plasma corticosterone levels in adult mouse offspring

14

. Furthermore, the

increased plasma corticosterone levels were concomitant with elevated adrenal levels of
StAR protein in female but not male adult offspring

14

. This gender-specific changes in

StAR expression is intriguing and begs the question of the molecular mechanisms that
underlie BPA-induced adrenal StAR expression in female offspring. Thus, the present
study was designed to address this important question using the H295A cell line, which is
currently the best available in vitro model of human fetal adrenal cortical cells. Using this
model, we have provided evidence indicating that BPA induces StAR protein expression
via an ER-mediated novel molecular mechanism that does not appear to involve StAR
gene transcription, translation or protein half-life.
The concentration range of BPA (1-10000 nM) used in the present study was consistent
with that used previously in vitro 41, and was lower than what was previously shown to
alter the steroidogenic pathway in non-adrenal cells

16-19

. Importantly, the 10 nM BPA

concentration (equivalent to 2.28 ng/ml) used throughout the present study is well within
the range previously reported in urine (0.16-43.42 ng/ml) 42 and plasma (0.5-22.3 ng/ml)
43

of pregnant women.

Since we previously demonstrated that prenatal BPA exposure led to increased StAR
protein levels in adrenal glands of female offspring 14, we sought first to validate our in
vitro model system. Indeed, we found that BPA increased StAR protein levels in a
concentration-dependent manner in H295A adrenal cortical cells. Previously, numerous
studies have examined the effects of BPA treatment on StAR protein levels in
reproductive organs with varying effects

22-27

. In vivo studies demonstrated decreased

StAR protein levels in the testes and ovaries of rodents after acute BPA exposure 22-25,27.
In contrast, Qiu et al. 26 observed increased StAR protein levels in the testes of male rats
after chronic BPA treatment. Thus, the effects of BPA exposure on StAR protein appear
to be organ-, tissue- and dose-specific. However, to date no studies have been reported to
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examine the molecular mechanisms by which BPA induced StAR expression in any
steroidogenic tissues or cells.
BPA has been shown to affect other key steroidogenic enzymes involved in adrenal
glucocorticoid production, including cyp11A1 and 3β-HSD

14,44,45

. We also examined

changes in these key enzymes, and found that protein levels of both cyp11A1 and 3βHSD were not altered by BPA treatment. It is interesting to note that we previously
reported that prenatal BPA exposure led to increased adrenal levels of cyp11A1 protein
in female but not male adult mouse offspring

14

. Furthermore, Lan et al.

45

used the

adrenal mouse cell line, Y1, as well as male mice treated with acute doses of BPA, and
demonstrated an increase in adrenal cyp11A1 protein levels. However, in H295R adrenal
cortical cells, only very high concentrations of BPA (10 µM) were shown to decrease
mRNA levels of cyp11A1 and 3β-HSD

44

. Thus, these discrepancies in BPA-induced

changes in cyp11A1 and 3β-HSD may be explained by differences in cell lines, treatment
regime, BPA doses/concentrations and exposure times. Taken together, these findings
suggest that BPA affects adrenal steroidogenesis primarily through altered StAR protein
expression.
BPA is a known agonist for ERβ, and has dual agonistic and antagonistic actions for
ERα, with a higher binding affinity to ERβ than to ERα 34,35. Additionally, human H295R
adrenal cortical cells have been shown to express both ERα and ERβ, with the latter
being the dominant receptor present 46. Therefore, we first examined the effects of BPA
on ERα and ERβ protein expression. We found that levels of both ERα and ERβ protein
were not changed after 48 hours of BPA treatment. ERα null mice showed increased
StAR levels in fetal and adult testes

47,48

. Additionally, male transgenic mice expressing

human aromatase, resulting in higher than normal levels of estrogen, had decreased StAR
levels

47,48

.However, whether a similar phenotype is present in the adrenal glands is

unknown. We then examined the effects of ERα- and ERβ-specific agonists, PPT and
DPN, on StAR protein. We found that both PPT and DPN increased StAR protein levels,
indicating that both ERα and ERb are involved in regulating StAR expression. To
determine if BPA signals through ER to increase StAR expression, cells were treated
with BPA in the presence and absence of the ER antagonist ICI. We found that ICI
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abrogated the stimulatory effects of BPA on StAR protein levels. Taken together, these
results suggest that BPA induces StAR protein expression via ERα and/or ERb in adrenal
cortical cells.
StAR is thought to be largely regulated transcriptionally, with numerous transcription
factors binding to the StAR promoter

15,37,40,49

. SF-1 is a master regulator of adrenal

steroidogenesis, since SF-1 null mice exhibited diminished basal levels of StAR 15,37,40,50.
Other key transcription factors involved in StAR regulation include C/EBPβ and Sp1
15,37,40

. Therefore, we investigated the effects of BPA on these three key transcription

factors. We found that protein levels of SF-1 were unchanged by BPA, which is
consistent with what we and others have previously demonstrated in experimental animal
models 14,51. In contrast, we found protein levels of C/EBPβ and Sp1 were increased after
48 hours of BPA treatment. Increased levels of C/EBPβ were also observed in 3T3-L1
pre-adipocyte cells after BPA treatment 52. C/EBPβ expression was decreased in livers of
53

male, but not female, offspring after prenatal BPA exposure

. Previously, Sp1 was

shown to be decreased in resorbed embryos but unchanged in viable embryos

54

. Taken

together, these findings suggest that BPA alters the expression of specific transcription
factors known to regulate StAR transcription.
As a first step in determining if BPA affects StAR transcription, we measured StAR
mRNA levels. StAR mRNA was found to be unchanged after 48 hours of BPA treatment.
This is consistent with a previous study in H295R adrenal cortical cells, which showed
that low concentrations of BPA (0.1-1 µM) did not affect StAR mRNA levels, while
higher concentrations of BPA (10 µM) decreased StAR mRNA

44

. Other studies in

reproductive tissues also demonstrated no significant changes in StAR mRNA after BPA
treatment

20,21

; however, StAR protein levels were not measured in those studies. In

contrast, numerous studies in reproductive cells showed altered StAR mRNA levels, but
results varied greatly in direction and magnitude of change

16-19

. Interestingly, StAR

protein levels have been shown to be altered, independent of changes in StAR mRNA,
after exposure to oxysterols

55

, pesticides

56

, endotoxins

57

and prostaglandins

58

;

however, the mechanisms behind these effects were not examined. Collectively, these
findings suggest that BPA regulate StAR primarily at post-transcriptional levels.
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Recent evidence has pointed to a potential post-transcriptional regulation of StAR

37,40

.

One potential player is AKAP149, a mitochondrial anchoring protein, which recruits
StAR mRNA to the OMM 37,38. AKAP149 at the OMM promotes the translation of StAR
by binding the 3’ untranslated region of StAR mRNA to the K homology (KH) RNAbinding motif 37,38,59. Therefore, we investigated the effects of BPA on AKAP149 protein
levels, which we found to be unaltered after 48 hours of BPA treatment. However, we
recognized that the activity of AKAP121/149 as well as protein levels and the activity of
other key translational regulators were not examined in this study. StAR mRNA is
translated into a 37-kDa pre-protein at the OMM

37,60

. Thus, to ascertain the effects of

BPA on StAR translation, we determined the level of the 37-kDa StAR pre-protein. We
did not observe any changes in the 37-kDa StAR pre-protein levels after treatment for 48
hours with BPA. Taken together, these results suggest that BPA does not affect the
translation of StAR protein in adrenal cortical cells.
To further investigate the molecular mechanisms underlying BPA-induced StAR protein
expression, we determined the effects of BPA on StAR protein degradation. The
degradation of the mature StAR protein occurs in the mitochondrial matrix by the two
proteases, LON and AG132, as well as one or more unknown mitochondrial proteases
61,62

. As an indicator of protein degradation, the half-life of 30-kDa StAR protein was

determined following treatment with BPA. No differences in the half-life of StAR protein
were observed between control and BPA-treated cells. Taken together, these results
indicate that BPA does not alter the degradation of StAR protein in H295A cells.
Collectively, the present findings suggest that BPA does not regulate StAR protein levels
through changes in transcription, translation or degradation. However, the regulation of
StAR is extremely complex and is not yet fully understood

37,49,63

. Thus, BPA may be

acting through an unknown mechanism to modulate StAR expression, and obviously
future studies will be required to examine this possibility. Additionally, due to the short
half-life of both StAR pre- and mature protein

64

, transcription and translation markers

were only examined at 48 hours, however it is possible that changes in mRNA or 37-kDa
StAR pre-protein could happen at earlier time points. Furthermore, we did not examine
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the effects of BPA on the cleavage of StAR or its transportation from the OMM to the
IMM. However, since we found no changes in the levels of 37-kDa StAR pre-protein, it
is unlikely that BPA affects either of these two steps. Furthermore, this study did not
measure the 32-kDa isoform of StAR protein, which, if changed, may provide a potential
explanation for BPA-induced changes in mature StAR protein levels 60,64.
In conclusion, the present study provides strong evidence that BPA signals through ERa
and/or ERb to increase StAR protein levels in H295A cells via an unknown mechanism
independent of StAR gene transcription, translation and protein half-life.

3.5
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4

1

BISPHENOL A STIMULATES ADRENAL CELL
PROLIFERATION THROUGH ERb-MEDIATED
ACTIVATION OF THE SONIC HEDGEHOG
SIGNALING PATHWAY1

The material in this chapter is based on a manuscript submitted to Journal of Steroid
Biochemistry and Molecular Biology: Medwid S, Guan H, Yang K. Bisphenol A
stimulates adrenal cortical cell proliferation via ERβ-mediated activation of the sonic
hedgehog signaling pathway (2017).
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4.1

Introduction

In Chapter 2, I observed an increase in adrenal gland weight in adult mouse offspring
prenatally exposed to BPA, with no changes in basal plasma ACTH levels. In this
chapter, I sought to determine the cellular and molecular mechanisms that underlie BPAinduced aberrant adrenal gland developmental phenotype using an in vitro cell model
system.
Bisphenol A (BPA) is one of the most well-known and prevalent endocrine disrupting
chemicals, and has gained universal attention due to its adverse effects in humans and
experimental animal models 1. BPA is widely used in the production of polycarbonate
plastics and epoxy resins, such as food and beverage storage containers and thermal paper
receipts

1,2

. Biomonitoring studies have detected BPA in human saliva, milk, serum and

urine collected globally 2. More alarming is the presence of BPA in human fetal blood,
placental tissue and amniotic fluid

2,3

. This has raised serious concerns about the impact

of BPA exposure on the developing fetus during the critical period of organ maturation.
Indeed, numerous studies have shown that BPA exerts adverse effects on many fetal
organ systems, including the brain
10,11

4,5

, lungs 6, liver 7, pancreas 8, heart 9, adrenal gland

, mammary gland 12,13, and ovary 14,15.

We recently showed that prenatal exposure to BPA resulted in altered adrenal gland
structure and function in adult mouse offspring

10

. Specifically, absolute and relative

adrenal gland weight was increased in both male and female adult offspring 10. Similarly,
Panagiotidou et al. reported adrenal hyperplasia in juvenile female rat offspring following
exposure to BPA during pregnancy and lactation

11

. Alterations in adrenal weight and

structure is normally associated with changes in plasma levels of adrenocorticotrophic
hormone (ACTH). However, we did not observe an increase in basal plasma levels of
ACTH, and concluded that BPA may directly affect adrenal gland weight independent of
plasma ACTH in our prenatally BPA exposed mouse model 10. BPA has previously been
shown to increase cell proliferation in various tissues, including breast cancer

16-18

,

ovarian cancer 19,20, neuroblastoma 21, Hela 22, prostate cancer 23, seminoma 24 and sertoli
cells 25. However, the effects of BPA on adrenal cortical cell proliferation has never been
examined.
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Sonic hedgehog (shh) signaling pathway is a key mediator of embryonic development, as
well as cell maintenance and tissue repair in adults

26,27

. Specifically, the shh pathway is

found to be activated during development, as well as in various forms of cancer due to its
role in promoting cell proliferation through direct transcriptional activation of
proliferation factors cyclin D1 and cyclin D2

26

. Shh signaling components (shh, Gli,

Patched 1) have been detected in human adrenal cortical cell lines, human fetal and adult
adrenal glands, as well as both pediatric and adult adrenal tumors

28,29

. Evidence of shh

involvement in adrenal cell proliferation is demonstrated by the presence of an adrenal
cortex hypotrophy phenotype in shh null mice

30,31

. Thus, the present study was

undertaken to determine (1) if BPA promotes adrenal cell proliferation, which may help
explain the increased adrenal gland weight phenotype we reported in our previous study
10

; and (2) if so, whether the stimulatory effects of BPA on adrenal cortical cell

proliferation are mediated through ERβ-mediated activation of the shh pathway using a
human adrenal cortical cell line as an in vitro model system.

4.2
4.2.1

Methods
Reagents

Bisphenol A was purchased from Sigma-Aldrich Canada Ltd. (CAS 80-05- 7; Oakville,
ON) and dissolved in ethanol to prepare 10 mM stock solution, and stored at -20°C.
Cyclopamine was purchased from Toronto Research Chemicals (C988400; Toronto,
ON), dissolved in ethanol to prepare 10 mM stock solution and stored at -20°C. 2,3-bis(4Hydroxyphenyl)-propionitrile

(DPN)

and

4-[2-Phenyl-5,7-

bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol (PHTPP) were purchased from
Tocris Bioscience (cat. no. 1494; Minneapolis, MN) and Abcam (ab145148; Toronto,
ON), respectively, dissolved in ethanol to a concentration of 100 mM, and stored at 20°C.

4.2.2

Cell Culture

The adrenocortical human cell line NCI-H295 cell line was derived from an adrenal
tumor of a 48-year-old female and was first described by Gazdar et al. 32. The NCI-H295
cell line expresses all steroidogenic enzymes present in the human fetal adrenal glands
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and is an established model to study adrenal steroidogenesis 33. The subline, NCI-H295A,
was further derived and characterized from the H295R cell line, and is currently the best
available model of human fetal adrenal gland cells 34. H295A cells (generously provided
by Dr. Walter L. Miller) were cultured in RPMI 1640 media (Invitrogen) with 2% fetal
bovine serum (FBS; Sigma), 0.1% insulin-transferrin-selenium supplement (Sigma
I18884) and 100IU penicillin and 100µg/mL were starved in serum-free media 24 h
before treatment, and cultured in 0.2% FBS media throughout treatments.

4.2.3

Western Blot Analysis

Levels of various proteins were analyzed using standard western blot analysis, as
previously described 35. Briefly, cells were lysed in SDS gel loading buffer (50mM TrisHCL, pH 6.8, 2% wt/vol SDS, 10% vol/vol glycerol, 100mM DTT and 0.1% wt/vol
bromophenol blue) to be loaded to a standard SDS-PAGE gel. Protein was then
transferred to a PVDF transfer membrane (Amersham Hybond-P, cat. no. RPN303F, GE
Healthcare Lifesciences, Baie D'Urfe, QC), and blocked overnight with 5% milk in TTBS
(0.1% vol/vol Tween-20 in TBS). Membranes were then probed with primary antibodies
for 1-2 hours at room temperature (Table 4.1). Washing was done with TTBS, 3×10
minutes before labeling with horseradish peroxidase-labeled secondary antibody (Table
4.1), for 1 hour at room temperature. After 3×10 minute TTBS washes, protein were
detected using ECL and visualized using chemiluminescence (cat. no. WBLUR0500,
Luminata Crescendo, Western HRP Substrate; Millipore, Etobicoke, ON) and captured
on the VersaDoc Imaging System (BioRad). Densitometry was performed using Image
Lab Software, comparing levels of proteins expressed as percent of controls.
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Table 4.1: Primary and secondary antibodies used for western blotting.
Antibody

Company

Catalog Number

Dilution Used

PCNA

Cell Signalling

2586

1:5000

GAPDH

Imgenex

IMG-5567

1:10000

Cyclin D1

Santa Cruz

Sc-717

1:500

Cyclin D2

Cell Signalling

3741

1:1000

ERβ

Santa Cruz

Sc-8974

1:1000

Gli1

Abcam

ab49314

1:500

Shh

Santa Cruz

β-tubulin

Imgenex

IMG-5810A

1:1000

Lamin B1

Abcam

Ab16048

1:20000

Anti-Rabbit

R&D systems

HAF008

1:3000

Anti-mouse

BIO RAD

170-6516

1:7500

Sc-365112

1:200
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4.2.4

Cell Number Assessment

Cells were seeded in 2% FBS-RMPI 1640 culture medium and were incubated overnight.
After 24 h serum starvation, the medium was changed to 0.2% FBS RMPI 1640
containing 10 nM BPA. After 72 h incubation, the cells trypsinized, added in equal
volumes to trypan blue stain 0.4% (Invitrogen T10282) and counted with Countess
Automated cell counter (Invitrogen C10277).

4.2.5

Real-time quantitative RT-PCR

The relative abundance of various mRNAs was determined by a two-step real time
quantitative RT-PCR (qRT-PCR), as described previously

36

, with the following

modifications. Briefly, total RNA was extracted from cells using RNeasy Mini Kit
(Qiagen Inc., Mississauga, ON) coupled with on-column DNase digestion with the
RNase-free DNase Set (Qiagen) according to the manufacturer’s instructions. One
microgram of total RNA was reverse-transcribed in a total volume of 20 µl using the
High Capacity cDNA Archive Kit (Applied Biosystems, Forest City, CA) following the
manufacturer’s instructions. For every RT reaction set, one RNA sample was set up
without reverse-transcriptase enzyme to provide a negative control. Gene transcript levels
of GAPDH, GLI1 and SHH were quantified separately by pre-designed and validated
TaqMan® Gene Expression Assays (Applied Biosystems; Table 4.2) following the
manufacturer’s instructions. Briefly, gene expression assays were performed with the
TaqMan® Gene Expression Master Mix (Applied Biosystems P/N #4369016) and the
universal thermal cycling condition (2 min at 50 °C and 10 min at 95 °C, followed by 40
cycles of 15 s at 95 °C and 1 min at 60 °C) on the ViiATM 7 Real-Time PCR System
(Applied Biosystems).
The relative amounts of various gene-specific mRNAs in each RNA sample was
quantified by the comparative CT method (also known as ΔΔ CT method) using the
Applied Biosystems relative quantitation and analysis software according to the
manufacturer’s instructions. For each experiment, gene specific mRNAs were normalized
to the housekeeping gene GAPDH. The amount of various gene-specific mRNAs under
different treatment conditions is expressed relative to the amount of transcript present in
the untreated control.
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Table 4.2: TaqMan® gene expression assays for the human genes analyzed.
Gene Name

Assay ID

SHH

Hs00179843_m1

GLI1

Hs00171790_m1

GAPDH

Hs02758991_g1
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4.2.6

Statistical Analysis

Results are presented as group means ± SEM of four independent experiments, as
indicated. Data was analyzed using a Student’s t-test or a one-way ANOVA, followed by
a Tukey’s post hoc; statistical significance was set at P<0.05. Statistical analysis was
performed using statistical software GraphPad Prism Version 5 Software.

4.3
4.3.1

Results
Time- and concentration-dependent effects of BPA on cell
proliferation.

As a first step in determining the effects of BPA on cell proliferation, protein levels of
PCNA, a universal marker of cell proliferation, were assessed over time. Levels of PCNA
protein were unchanged at 24 and 48 h, but were significantly elevated at 72 h following
treatment with 10 nM of BPA (Figure 4.1A). A similar trend of change was observed in
cell number following BPA treatment (Figure 4.1B). We then treated cells with
increasing concentrations of BPA (1-1000 nM) for 72 h, and showed that this treatment
resulted in a concentration-dependent increase in PCNA protein levels such that the
maximal effect was observed at 10 nM BPA (Figure 4.1C).
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Figure 4.1: Time- and concentration-dependent effects of BPA on cell proliferation.
H295A cells were treated with 10 nM of BPA for various times (24-72 h) or increasing
concentrations (1-1000 nM) of BPA for 72 h. At the end of treatment, levels of PCNA (a
universal marker of proliferation) (A, C) and cell number (B) were determined by
western blotting and cell counting, respectively. Data are presented as mean ± SEM
(*P<0.05, ***P<0.001 vs. control; n=4 independent experiments).
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4.3.2

Effects of BPA on the expression of key cell proliferation
factors.

To further examine the effects of BPA on cell proliferation, protein levels of the two key
proliferation factors, cyclin D1 and cyclin D2, were determined. Although levels of both
cyclin D1 and cyclin D2 proteins were unchanged after 48 h of BPA treatment (Figure
4.2A), they were significantly increased after 72 h of BPA treatment (Figure 4.2B).
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Figure 4.2: Effects of BPA on key cell proliferation factors.
H295A cells were treated with 10 nM of BPA for 48 h (A) or 72 h (B). At the end of
treatment, levels of the two key cell proliferation factors, cyclin D1 and cyclin D2 were
determined by western blotting. Data are presented as mean ± SEM (**P<0.01 vs.
control; n=4 independent experiments).
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4.3.3

Effects of BPA on selected components of the shh signaling
pathway.

Shh signaling is known to be essential for adrenal development and proliferation. Adrenal
specific shh knockout mice display severe adrenal hypoplasia, specifically an
underdeveloped cortex in fetal and adult mice 30,37. To explore the role of shh signaling in
mediating BPA-induced cell proliferation, changes in key shh signaling pathway
components were examined. Levels of shh mRNA, but not Gli1 mRNA, were increased
at 48 h post BPA treatment (Figure 4.3A&B). In contrast, protein levels of both shh and
Gli1 were elevated following 48 h of BPA treatment (Figure 4.3C&D), which returned
to control levels at 72 h (Figure 4.3E&F).
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Figure 4.3: Effects of BPA on selected components of the shh signaling pathway.
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, levels of
shh mRNA (A) and Gli1 mRNA (B) were determined by qRT-PCR. Levels of shh
protein (C&E) and Gli1 protein (D&F) at 48 h (C&D) and 72 h (E&F) were determined
by western blotting. Data are presented as mean ± SEM (*P<0.05, **P<0.01, vs. control;
n=4 independent experiments).
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4.3.4

Effects of BPA on activity of the shh signaling pathway.

Activation of the shh signaling pathway involves translocation of the shh transcription
factor Gli1 from cytoplasm to the nucleus where it acts as an activator of shh target genes
38,39

. To determine if BPA activates the shh signaling pathway, we measured Gli1 protein

levels in cytosolic and nuclear fractions following treatment with BPA for 48 h. BPA
treatment significantly increased Gli1 protein in nuclear but not cytosolic fraction
(Figure 4.4A&B). To ascertain if BPA activation of the shh signaling pathway is liganddependent, we used cyclopamine (Cyc), which blocks the shh pathway at the SMO
receptor. We treated cells with BPA in the presence and absence of Cyc, and examined
changes in Gli1 protein. We found that Cyc prevented BPA-induced increases in Gli1
protein levels (Figure 4.4C).
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Figure 4.4: Effects of BPA on activity of the shh signaling pathway
H295A cells were treated with 10 nM BPA for 48 h. At the end of the treatment, levels of
Gli1 protein in cytosolic (A) and nuclear (B) extracts were determined by western
blotting. Alternatively, H295A cells were treated with either 10 nM BPA, 10 µM
cyclopamine (Cyc) or both for 48 h. At the end of treatment, levels of Gli1 protein were
determined by western blotting (C). Data are presented as mean ± SEM (*P<0.05 vs.
control; different letters indicate statistically significant differences among groups; n=4
independent experiments).
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4.3.5

Effects of shh pathway inhibition on BPA-induced cell
proliferation markers.

Shh signaling is known to induce cell proliferation in a variety of tissues

26,40,41

.

Specifically, the transcription factor Gli1 is known to directly stimulate the transcription
of cyclin D1 and D2 genes, CCND1 and CCND2 26. To provide functional evidence for
the involvement of the shh signaling pathway in mediating BPA-induced cell
proliferation, we assessed changes in protein levels of PCNA, cyclin D1 and D2
following treatment with BPA in the presence and absence of the shh pathway inhibitor
Cyc. Cyc completely blocked BPA-induced increases in protein levels of PCNA (Figure
4.5A), as well as cyclin D1 and D2 (Figure 4.5B).
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Figure 4.5: Effects of shh inhibition on BPA-induced cell proliferation markers.
H295A cells were treated with 10 nM BPA, 10 µM cyclopamine (Cyc) or both for 72 h.
At the end of treatment, levels of PCNA (A), cyclin D1 and cyclin D2 (B) were
determined by western blotting. Data are presented as mean ± SEM (Different letters
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4.3.6

Effects of BPA on estrogen receptor β expression and
activity

The translocation of ER from cytosol to the nucleus is essential for transcriptional
activation of estrogen target genes

42-44

. To examine if BPA activates ERβ, we measured

protein levels of ERβ in total cell lysates as well as cytosolic and nuclear fractions
following BPA treatment for 48 h. Although BPA treatment did not alter total ERβ
protein levels (Figure 4.6A), it decreased cytosolic while increasing nuclear levels of
ERβ protein (Figure 4.6B&C).
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Figure 4.6: Effects of BPA on estrogen receptor β expression and activity.
H295A cells were treated with 10 nM of BPA for 48 h. At the end of treatment, levels of
ERβ protein in total (A) cytosolic (B) and nuclear (C) extracts were subjected to western
blotting. Data are presented as mean ± SEM (**P<.0.01 vs. control; n= 4 independent
experiments).
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4.3.7

Effects of DPN and PHTPP on BPA-induced cell proliferation
markers.

We then investigated the involvement of ERβ in BPA-induced cell proliferation using the
ERβ specific agonist DPN and the ERβ specific antagonist PHTPP. Treatment with DPN
significantly increased protein levels of PCNA (Figure 4.7A) as well as cyclin D1 and
cyclin D2 (Figure 4.7C) at 72 h. Furthermore, pretreatment with PHTPP completely
prevented BPA-induced increases in levels of PCNA (Figure 4.7B), cyclin D1 and cyclin
D2 (Figure 4.7D) proteins.
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Figure 4.7: Effects of DPN and PHTPP on BPA-induced cell proliferation markers.
H295A cells were treated with 10 nM DPN, 10 nM BPA, 100 nM PHTPP, or both
PHTPP and BPA for 72 h. At the end of treatment, levels of PCNA protein (A&B),
cyclin D1 and cyclin D2 protein (C&D) were determined by western blotting. Data are
presented as mean ± SEM (**P<0.01, ***P<0.001 vs. control; different letters indicate
statistically significant differences among groups; n=4 independent experiments).
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4.3.8

Effects of DPN and PHTPP on BPA-induced activation of the
shh signaling pathway.

ERa has been shown to increase shh activity in breast

45,46

and gastric

47

cancer cells.

However, this effect has yet to be shown with ERβ. Therefore, we tested the hypothesis
that BPA acts through ERβ to activate the shh signaling pathway. We showed that the
ERβ specific agonist DPN increased protein levels of both shh and Gli1 after 48 h
treatment (Figure 4.8A&C). Importantly, the ERβ specific antagonist PHTPP completely
blocked BPA-induced increases in both shh and Gli1 protein levels (Figure 4.8B&D).
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Figure 4.8 Effects of DPN and PHTPP on BPA-induced shh pathway activation.
H295A cells were treated with 10 nM DPN, 10 nM BPA, 100 nM PHTPP, or both
PHTPP and BPA for 48 h. At the end of treatment, levels of shh protein (A&B) and Gli1
protein (C&D) were determined by western blotting. Data are presented as mean ± SEM
(**P<0.01 vs. control; different letters indicate statistically significant differences among
groups; n=4 independent experiments).

150

4.4

Discussions

Proper adrenal gland development is essential for adrenal steroidogenesis, particularly
glucocorticoid production in later-life. We recently demonstrated that prenatal exposure
to BPA resulted in abnormal adrenal gland development and function in adult mouse
offspring, including increased adrenal gland weight independent of plasma ACTH levels
10

. However, the molecular mechanisms underlying the BPA-induced increase in adrenal

gland weight remain unknown. Therefore, the present study was designed to address this
important question using the best available model of fetal adrenal cortical cells, the
H295A cell line. We have demonstrated that BPA stimulates adrenal cell proliferation via
ERβ-mediated activation of the shh signaling pathway. Thus, our present findings reveal
a plausible molecular mechanism by which BPA influences adrenal gland development
and function.
The concentration of BPA used in this study (10 nM) is in line with those used in
previous in vitro studies 48. Importantly, this concentration (equivalent to 2.28 ng/ml) is
well within the range previously reported in plasma (0.5-22.3 ng/ml)

49

and urine (0.16-

43.42 ng/ml) 50 of pregnant women in North American.
BPA has been shown to influence cell proliferation in both in vivo and in vitro models. In
experimental animal models, prenatal exposure to BPA led to increased cell proliferation
in fetal liver 7, prostate 51, pancreas 52, and pituitary gland 53. In contrast, offspring of rats
exposed to BPA during pregnancy and lactation showed decreased proliferation in neural
stem cells of the hypothalamus and sub-ventricular zone

54

BPA increases cell proliferation at various concentrations

. In several in vitro models,

16-25

. Interestingly, in sertoli

cells, nanomolar concentrations of BPA induced cell proliferation, while micromolar
concentrations decreased cell proliferation, suggesting that the effect of BPA on cell
proliferation is concentration-dependent 55. To the best of our knowledge, we are the first
to demonstrate that BPA, at environmentally relevant concentrations, significantly
increases cell number as well as the expression of PCNA, cyclin D1 and D2, three key
markers of cell proliferation, in adrenal cortical cells. This indicates that BPA stimulates
adrenal cortical cell proliferation. Thus, our present study provides a plausible cellular

151

mechanism by which prenatal BPA exposure results in increased adrenal gland weight in
adult mouse offspring 10.
Activation of the shh signaling pathway is known to increase the transcription of genes
encoding both cyclin D1 and D2 genes, leading to increased cell proliferation

26

.

Recently, BPA has been shown to increase levels of microRNA-107 (miRNA-107),
which inhibits the expression of suppressor of fused homolog (SUFU) and GLI family
zinc finger 3 (Gli3) in human endometrial cancer in RL95-2 cells 56. Both SUFU and Gli3
are repressors of the shh signaling pathway, thus BPA-induced suppression of these
proteins may potentially lead to the activation of shh signaling and consequently
increased proliferation in endometrial cells

56

. Therefore, we investigated the possibility

that the BPA-induced adrenal cortical cell proliferation may be mediated via activation of
the shh signaling pathway. As a first step in examining this possibility, we determined the
effects of BPA on shh expression, and found that levels of both shh mRNA and protein
were increased after 48 hours of BPA treatment, which preceded the increase in cell
proliferation we observed at 72 hours.
An increase in shh protein and secretion results in its binding to the transmembrane
receptor Patched 1 (Ptch1), which prevents Ptch1 from inhibiting another transmembrane
protein smoothened (SMO)

38,39

. SMO can then be released from the plasma membrane

into the cytoplasm, leading to the release of a complex containing the transcription
factors Gli1-3, allowing them to translocate to the nucleus to regulate transcription of
target genes

38,39

. Specifically, the nuclear translocation of the positive transcriptional

regulator Gli1, is considered a marker of shh signaling activation

38,39

. Therefore, we

investigated the potential for BPA to alter Gli1 protein and mRNA levels. We found that
although BPA did not alter Gli1 mRNA, it increased Gli1 protein levels at 48 hours. The
regulation of Gli1 at post-transcriptional level is well established and could be a result of
changes in translation and phosphorylation efficiency

57,58

. Furthermore, BPA

significantly increased Gli1 protein levels in the nuclear fraction without altering those in
the cytosolic fraction, suggesting that BPA enhanced nuclear translocation of Gli1, and
consequently the activity of the shh signaling pathway. Given the observed increase in
Gli1 protein levels in total cell lysates, the relatively minor and non-significant decrease
seen in cytosolic Gli1 levels is consistent with our notion of an enhanced Gli1 nuclear
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translocation following BPA treatment. It is known that activation of the shh signaling
pathway is mediated through either the ligand-dependent or the ligand-independent
pathway

59

. To determine if BPA acts through the ligand-dependent shh signaling

pathway, we examined the effects of BPA on Gli1 protein levels in the presence and
absence of cyclopamine. Cyclopamine is a potent inhibitor of the shh signaling pathway
by preventing release and translocation of the SMO receptor. In the present study, we
showed that cyclopamine blocked the effects of BPA on Gli1 protein levels, indicating
that BPA activates the shh pathway through the ligand-dependent pathway.
To ascertain whether BPA-induced activation of the shh signaling pathway leads to
increased cell proliferation, we treated cells with BPA in the presence and absence of
cyclopamine. We found that cyclopamine completely abrogated the stimulatory effects of
BPA on cell proliferation, as indicated in protein levels of PCNA, cyclin D1 and D2.
Taken together, these results demonstrate the involvement of the shh signaling pathway
in BPA-induced adrenal cortical cell proliferation.
It is well known that BPA acts as an ERβ agonist, with a higher affinity for ERβ than
ERa

60,61

. Furthermore, ERβ is the dominant estrogen receptor expressed in human

H295R adrenal cortical cells 62. Therefore, we then investigated the role of ERβ in BPAinduced cell proliferation and shh activation. Given that a key step in ERβ activation is its
rapid nuclear translocation upon binding to its ligand

63

, we determined the effects of

BPA on ERβ translocation at 48 h. This time point was chosen based on the BPAinduced increase in shh mRNA at 48 h. We found that levels of ERβ protein were
increased in the nuclear fraction but decreased in the cytosolic fraction following BPA
treatment, indicating that BPA enhanced translocation of ERβ to the nucleus in H295A
cells. However, it is likely that the BPA-induced increase in ERβ nuclear translocation
may have occurred earlier than 48 h.
Although estrogen has previously been shown to increase adrenal cell proliferation in
both animal models

64

and the H295R cell line

62

. We then sought to determine if

activation of ERβ stimulates adrenal cell proliferation using the ERβ selective agonist
DPN. We showed that DPN increased protein levels of the three key proliferation
markers, PCNA, cyclin D1 and D2, indicating that the activation of ERβ by DPN led to
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increased cell proliferation. To provide evidence for the involvement of ERβ in mediating
BPA-induced cell proliferation, we treated cells with BPA in the presence and absence of
the ERβ-specific antagonist PHTPP. We found that PHTPP completely blocked the
stimulatory effects of BPA on PCNA, cyclin D1 and D2 protein. Taken together, these
results demonstrate that ERβ mediates BPA-induced proliferation in adrenal cells.
The ability of estradiol to activate the shh signaling pathway has previously been
demonstrated in ERa positive breast and gastric cancer cells

45-47

, however it remains

unknown if a similar effect can be observed through ERβ. Therefore, to determine if ERβ
activates the shh signaling pathway in adrenal cells, we examined the effects of ERβ
specific agonist DPN on expression of the two key proteins in the shh signaling pathway.
We found that DPN increased both shh and Gli1 protein levels, indicating a novel link
between ERβ and shh activation. We then determined if the activation of ERβ by BPA
leads to activation of the shh signaling pathway. We treated cells with BPA in the
presence and absence of ERβ-specific antagonist PHTPP, and found that PHTPP
abrogated the stimulatory effects of BPA on shh and Gli1 protein levels. Collectively,
these results indicate that BPA stimulates adrenal cell proliferation via ERβ-induced
activation of the shh signaling pathway.
In conclusion, the present study demonstrates for the first time that BPA acts on ERβ to
activate the shh signaling pathway, which in turn leads to increased proliferation in
H295A cells. Thus, our present study reveals a novel BPA-induced cell proliferation
signalling pathway that may underlie the increased adrenal gland weight phenotype we
reported previously in prenatally BPA exposed adult mouse offspring.
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5.1

Summary

This thesis utilizes both in vivo and in vitro approaches aimed at determining the effects
of prenatal exposure to environmentally relevant doses of BPA on adrenal gland
development and steroidogenic function. Prenatal exposure to BPA resulted in altered
adrenal steroidogenesis, as evidenced by increased plasma corticosterone levels.
However, there were no corresponding changes in plasma levels of ACTH. The increased
plasma corticosterone in female offspring was likely a result of enhanced adrenal
expression of StAR, the rate limiting factor of steroidogenesis. However, adrenal StAR
expression was not altered in male offspring, suggesting that BPA exerted sex-specific
effects on adrenal StAR expression. Using the H295A cell line as an in vitro model
system, I demonstrated that BPA induced StAR protein expression through an ERaand/or ERb-mediated unknown mechanism that was independent of transcription,
translation, and protein half-life. I also provided evidence that BPA increased adrenal
cortical cell proliferation in vitro via a novel molecular mechanism that involves ERbmediated activation of the Shh signaling pathway. Taken together, these findings
demonstrate that prenatal BPA exposure at environmentally relevant doses disrupts
adrenal gland development and steroidogenic function specifically pertaining to
glucocorticoid production. They also suggest that BPA-induced aberrant adrenal gland
development and steroidogenic function help explain alterations in plasma glucocorticoid
levels and HPA dysfunction seen in epidemiological
3-6

1,2

and experimental animal studies

.

5.1.1

Doses and concentrations of BPA used in in vivo and in vitro
experiments

The dose of BPA used in Chapter 2 (25 mg BPA/kg diet; equivalent to 5 mg BPA/kg
body weight) was chosen based on our previous prenatal exposure dose-response studies
in which impaired fetal lung, pancreas, and liver maturation were induced without any
effect on fetal body weight or litter size

7-9

. This dose is also one tenth of the LOAEL

reported for rodents (50 mg/kg/day), as determined by the U.S. Environmental Protection
Agency (IRIS 2012). Importantly, maternal plasma concentrations of BPA in our mouse
model were determined to be 1.7 ng/ml, measured using GC–MS 7. The concentration of
BPA (10 nM) used throughout Chapters 3 and 4 is equivalent to 2.28 ng/ml, which is
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consistent with previous in vitro studies 10. The doses and concentrations of BPA used in
both in vivo and in vitro experiments are at the lower end of the exposure range reported
in the plasma (0.5-22.3 ng/ml)

11

and urine (0.16-43.42ng/ml)

1,2

of pregnant women in

the North America. Additionally, pharmacokinetic studies have shown that oral
administration of unconjugated BPA resulted in similar plasma levels in rodents and nonhuman primates 12. Thus, the dosages of BPA as well as the mouse model and the adrenal
cortical cell line used in this thesis are relevant to human exposure.

5.1.2

Prenatal BPA disrupts adrenal steroidogenesis in a sexspecific manner

Exposure to EDC during critical periods of organ maturation affect lifelong organ
structure and function, leading to disease and dysfunction later in life

13,14

. Evidence

suggests that EDC exposure during fetal development can lead to HPA axis programming
alterations, resulting in HPA and adrenal dysfunction in adulthood 15,16. As such, prenatal
BPA exposure in humans is associated with HPA axis dysfunction in both pregnant
women and 3-month old infants 1,2. In addition, animal studies have shown that perinatal
BPA exposure caused HPA dysfunction in adult offspring, resulting in changed gene
expression in the hypothalamus and pituitary, and altered plasma levels of CRH, ACTH,
and glucocorticoid

3-6

. Moreover, Panagiotidou, et al. 6 demonstrated that BPA exposure

during pregnancy and lactation resulted in increased adrenal gland weight and abnormal
adrenal cortex zone thickness. Taken together, these findings suggest that developmental
exposure to BPA can disrupt the HPA axis and adrenal gland development, leading to
altered adrenal function in adulthood.
In Chapter 2, the effects of developmental BPA exposure on adrenal function were
assessed by examining the hypothesis that prenatal exposure to environmentally relevant
doses of BPA disrupts adrenal gland development and steroidogenic function in adult
mouse offspring. This study demonstrated that prenatal BPA exposure led to increased
basal plasma corticosterone levels independent of ACTH levels in both male and female
adult offspring. However, protein levels of StAR and cyp11A1, the two rate limiting
factors of steroidogenesis, were only increased in female offspring adrenal glands,
demonstrating the sex-specific effects of BPA.
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These findings are supported by numerous studies demonstrating the adverse effects of
other environmental chemicals on adrenal steroidogenesis. As described in Table 5.1,
pesticides, fungicides and insecticides (atrazine, imazalil, prochloraz, lindane, and 3methylsulfonyl-2,2-bis(4-chlorophenyl)-1,1-dichloroethene
phytoestrogens (diadzein and geinstein)

18,21,22

(3-MeSO2-DDE))

17-23

,

, organophosphates (Diethylumbelliferyl

phosphate and dimethoate) 18,24,25, nicotine 26, cadmium 18, mercury 27, and nonlyphenol 28
have all been shown to alter adrenal steroidogenesis by disturbing steroidogenic enzymes
and the downstream production of steroid hormone levels.
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Table 5.1: Environmental chemicals that alter adrenal steroidogenesis.
Environmental chemical

Structural/ functional impact

Reference

Atrazine

Cyp19 inducer

17
19

Inhibit steroidogenic enzymes
Imazalil

21,22

Decreased cortisol and aldosterone
secretion

Prochloraz
Lindane
3-MeSO2-DDE

Inhibit cortisol and aldosterone
secretion through inhibition of cyp17
Increased steroidogenic enzymes and

20

StAR promotor activity
Inhibit cortisol secretion through

18,23

interaction with cyp11B1
Inhibit activity but not expression of

Diadzein

18

21,22

3b-HSD
Decreased cortisol and aldosterone

18

secretion
Geinstein

Diethylumbelliferyl phosphate

Inhibit activity but not expression of
3b-HSD
Decreased cortisol and aldosterone

Nicotine
Cadmium
Mercury

18

secretion
Inhibited StAR transcription

25

Inhibit transcription of StAR

26

Decreased cortisol and aldosterone

18

secretion
Inhibit testosterone and progesterone

27

levels
Decreased progesterone and increased

4-nonylphenol

18

secretion
Decreased cortisol and aldosterone

Dimethoate

21,22

testosterone and 17b-estradiol levels

28
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Importantly, evidence suggests that dysfunction of the HPA axis during fetal
development results in increased glucocorticoid levels in adults, leading to an increased
risk for depression and other mood disorders

29,30

. Thus, these studies provide a possible

mechanism behind BPA’s association with neurological and behavioural disorders such
as depression and anxiety 5,31.
Feedback and signaling pathways are essential for maintaining proper adrenal gland
development and function, and thus any alterations in these pathways may lead to disease
and dysfunction

32-35

.

Furthermore, there are a variety of transcription factors and

receptors that are essential for proper developmental processes and can be altered during
the critical period of organogenesis

32,33

. Previous experimental animal studies have

provided evidence for an important role of the following factors and signaling pathways
in adrenal development: (1) steroid hormone receptors such as ER

36

and glucocorticoid

receptors 33; (2) Shh 37 and IGF signaling 38; and (3) transcription factors, such as SF-1 39
and DAX-1 40. Alterations in any of these factors result in abnormal adrenal development
and can potentially lead to altered adrenal function in adult life. Therefore, it is likely that
prenatal BPA disrupts fetal adrenal development by altering one or more of these factors
and signaling pathways.

5.1.3

BPA stimulates StAR protein expression through estrogen
receptor signaling

In Chapter 2, I demonstrated that prenatal BPA exposure increased expression of the ratelimiting factor of adrenal steroidogenesis, StAR, in adult female mouse offspring

41

.

Therefore, H295A cells, the best available model of human fetal adrenal cortical cells,
were used an in vitro model system to investigate the underlying molecular mechanisms.
As shown in Chapter 3, BPA treatment increased StAR protein levels in a concentrationdependent manner, indicating that these cells were a suitable in vitro model system.
Chronic induction of the rate-limiting step of adrenal steroidogenesis, StAR, suggests a
permanent upregulation of the steroidogenic pathway. This would result in an increase in
the production of glucocorticoids, which may lead to long term diseases such as
depression, anxiety, metabolic dysfunction, and glucocorticoid resistance. Additionally,
this sustained increase in adrenal steroidogenesis would suggest that BPA may disrupt
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HPA axis function. This is consistent with previous literature suggesting BPA affects the
HPA axis at the level of the hypothalamus and pituitary gland 3,5.
Since the ER pathway has been shown to be critical for adrenal gland development,
specifically for cortical development and ACTH receptor sensitivity

42

, the possible

involvement of ER signaling was examined with BPA treatment. The ERa and ERb
isoform specific agonists PPT and DPN, respectively, were used to determine if ERa
and/or ERb were involved in regulating StAR expression. I demonstrated that both PPT
and DPN mimicked while the ER antagonist ICI blocked the stimulatory effects of BPA
on StAR protein levels. These findings suggested that the BPA-induced StAR protein
expression is likely mediated by ERa and/or ERb. They also revealed a novel role of
these two nuclear ERs in regulating adrenal StAR expression, and consequently adrenal
steroidogenesis.
I then elucidated the precise molecular mechanism by which BPA, via ERs, induces
StAR protein expression. First, I examined if BPA could be interfering with the
transcription of StAR mRNA, and found that levels of StAR mRNA were unchanged
after BPA treatment. This suggested that BPA did not affect StAR gene transcription.
Previous studies have found that StAR protein levels can be altered independent of
changes in StAR mRNA after exposure to oxysterols 43, pesticides 44, endotoxins
prostaglandins

46

45

and

. However, the post-transcriptional mechanisms behind these effects

were not examined.
Next, I examined if BPA altered the translation of the 37-kDa StAR pre-protein, which
was found to be unchanged after BPA exposure, suggesting that BPA did not alter StAR
translation. The StAR pre-protein is cleaved into the mature 30-kDa isoform at the OMM
and transported to the IMM following cholesterol transport 47,48. If BPA interfered in the
processes of StAR cleavage or transport, there would not only be a change in the mature
StAR protein levels but also a reciprocal change in the 37-kDa pre-protein. Therefore,
since there was no change in StAR pre-protein levels, it is unlikely that BPA affected
StAR cleavage or transport.

167

Lastly, I determined if BPA affected the half-life of StAR protein, and found that it was
unchanged following BPA treatment. An increase in mature StAR protein build-up in the
mitochondria is normally associated with an increase in corresponding proteases (LON
and AFG3L2) responsible for StAR degradation to prevent a novel form of mitochondrial
stress, termed StAR overload response (SOR)

49,50

. Thus, the BPA-induced increase in

StAR protein levels independent of alterations in the half-life of StAR protein suggests
that BPA may alter the SOR. This buildup of StAR protein in the mitochondria may lead
to alterations in mitochondria structure and function 49.
Collectively, these findings suggest that BPA increases StAR protein levels likely
through ERa and/or ERb

in adrenal cortical cells that involve an unknown novel

mechanism independent of StAR gene transcription, translation, and protein half-life.
Nevertheless, BPA-induced increases in StAR protein suggest the induction of adrenal
steroidogenesis, and consequently an increase in glucocorticoid production. However,
future research is required to decipher the precise molecular mechanisms behind these
effects to help better understand the adverse effects of BPA, as well as other EDCs, on
adrenal gland steroidogenesis.

5.1.4

BPA stimulates adrenal cortical cell proliferation through
ERb-mediated activation of the Shh pathway

In Chapter 2, I demonstrated that prenatal BPA exposure increased both absolute and
relative adrenal gland weight without a change in plasma ACTH levels in adult mouse
offspring 41. Increased adrenal weight is normally a result of high plasma ACTH levels 51.
However, I did not observe an increase in basal plasma levels of ACTH, and concluded
that BPA likely affects adrenal gland weight independent of ACTH in our prenatal BPA
exposed mouse model

41

. Therefore, I addressed this possibility in Chapter 4 using the

H295A cell line as an in vitro model system. Proliferation in the adrenal gland is essential
for development and remodeling in the adult

35,52

. I demonstrated that BPA treatment of

H295A cells induced proliferation, as evidenced by increased levels of PCNA (a
universal proliferation marker), and key proliferation factors cyclins D1 and D2.
The Shh signaling pathway is heavily involved in the development and formation of the
adrenal glands, and Shh knockout mice display a severe hypotrophic adrenal gland
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phenotype

37,53

. Furthermore, Shh signaling has been shown to induce proliferation in

other cell types, by increasing transcription of cyclin D1 and D2 genes 54. Analysis of the
Shh signaling pathway showed that BPA increased mRNA and protein levels of Shh, as
well as protein levels and activity (determined by nuclear translocation) of Gli1, a key
transcription factor in the Shh signaling pathway. Additionally, inhibition of the Shh
pathway by cyclopamine, a well-known Shh signaling pathway antagonist, blocked BPAinduced increase in proliferation. Collectively, these results suggest that BPA activates
Shh signaling to increase adrenal cortical cell proliferation. Shh signaling pathway is not
only important for cell proliferation but is involved in a variety of other developmental
processes that may be altered due to BPA exposure

54

. Previous studies have

demonstrated altered Shh levels in adrenal tumors in both adult and pediatric patients,
indicating its involvement in adrenal cancer, and suggesting that BPA may increase the
risk of adrenal carcinoma tumors 55,56.
The ability of estrogen to activate Shh signaling has previously been shown in breast and
gastric cancer cells 57-59. Therefore, I examined the hypothesis that BPA increases adrenal
cell proliferation through ERb-mediated activation of the Shh pathway. As shown in
Chapter 4, the ERb-specific antagonist PHTPP blocked the stimulatory effects of BPA on
PCNA, cyclin D1, and cyclin D2 levels, suggesting that ERb is involved in mediating
BPA-induced adrenal cell proliferation. Furthermore, PHTPP was also shown to prevent
the stimulatory effects of BPA on Shh and Gli1 protein levels, linking ERb to the
activating the Shh signaling pathway following BPA treatment. This is consistent with
previously reported findings that estrogen activates the Shh signaling pathway through
ERa 57-59. However, my findings demonstrate for the first time that ERb, through a direct
or indirect mechanism, regulates the Shh signaling pathway.
Taken together, these findings suggest that BPA acting through ERb activates the Shh
signaling pathway and results in increased adrenal cortical cell proliferation (Figure 5.1).
Changes and dysregulation in cell proliferation have previously been associated with
increased risk of cancer in numerous tissues

35,54,60

. As well, BPA has been shown to be

associated with various types of cancers in both human and experimental animal studies
61-63

. Therefore, it is tempting to speculate that an increase in adrenal cell proliferation
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could lead to an increased risk of adrenal cortical cancer. Moreover, higher levels of
adrenal proliferation in vitro suggest an increased potential for steroid hormone
production. If these findings could be extrapolated to humans, it is conceivable that
prenatal BPA exposure could lead to chronically elevated glucocorticoid levels. In
addition, due to the ubiquitous nature of both Shh and ER expression, there is the
potential that this novel BPA signaling pathway induced cell proliferation may be
applicable to other tissues, leading to numerous risks, including an increased risk of
cancer.
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Figure 5.1: A schematic representation of the postulated molecular pathway by
which BPA stimulates adrenal cortical cell proliferation.
BPA readily crosses the cell membrane into the cytoplasm where it binds to and activates
ERβ. The activated ERβ translocates to the nucleus where it promotes transcription of the
shh gene, leading to increased shh mRNA and protein. Shh is secreted, acts in an
autocrine/paracrine fashion and binds to Ptch1 receptor, preventing Ptch1 from inhibiting
SMO. SMO is then released from the plasma membrane into the cytoplasm, leading to
the release of a complex containing the key shh transcription factor Gli1. Gli1
translocates to the nucleus where it binds to the promoters of key proliferation factors,
such as CCND1 and CCND2, and enhances their transcription, and ultimately leading
to increased cell proliferation.
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5.2

Future Directions

The findings reported in this thesis reveal an important role of prenatal BPA in altering
adrenal gland development and steroidogenic function in adult mouse offspring, and
defines novel mechanisms of BPA actions in stimulating both adrenal StAR expression
and adrenal cortical cell proliferation. However, it is important to recognize there are
numerous important questions that need to be addressed, and are discussed below.

5.2.1

To study the effects of prenatal BPA on the other
components of the steroidogenic pathway

The ZG is essential for the production of the steroid hormone aldosterone, which acts on
the distal tubule and collecting duct of the kidney to promote sodium reabsorption

64-66

.

Aldosterone is synthesized from corticosterone by the enzyme Cyp11B2, localized in the
ZG, as part of adrenal steroidogenesis (Figure 1.8)

64-66

. The regulation of aldosterone

production is not only controlled by ACTH, but is also regulated by angiotensin II and
potassium levels 64,65. Moreover, changes in aldosterone levels can result in altered blood
pressure due to its actions on sodium reabsorption 64,65. Indeed, epidemiological evidence
suggests an association between high BPA levels in plasma/urine and hypertension

67,68

.

However, there are currently no known studies that have examined the effects of BPA on
aldosterone or Cyp11B2 levels. Thus, it is of importance to determine the potential
effects of BPA on aldosterone production and regulation, and to examine the
physiological consequences these effects may have.
The adrenal glands are also essential in producing precursors to sex hormones, such as
DHEA from the ZR

64,66

. DHEA is not only required for the synthesis of estrogens and

testosterone in the adult reproductive system, but is critical for estrogen production by the
placenta during fetal development 64,66. Previous studies using an adult adrenal gland cell
line (H295R) have demonstrated that BPA treatment resulted in altered levels of
progesterone, testosterone, estrone, and estradiol

69

. However, the effects of prenatal

BPA on DHEA levels in the adrenal glands and the potential mechanism behind these
effects are largely unknown. Therefore, further investigation into the effects and
mechanism of BPA’s actions on steroid hormones other than glucocorticoids in the fetal
and adult adrenal gland, and the long-term consequences of these effects, is warranted.
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5.2.2

To determine the precise molecular mechanism behind the
effects of BPA on StAR protein levels

In Chapter 3, I was not able to completely elucidate the potential molecular mechanism
underlying the effect of BPA on StAR protein levels. However, I suggest that BPA does
not affect the gene transcription, translation, or protein half-life of StAR. Thus, further
research is warranted to examine the effects of BPA on StAR regulation in human
adrenocortical cells due to its essential role as the rate-limiting step in adrenal
steroidogenesis

47,70

. The mechanisms underlying StAR regulation are not yet fully

understood, and new mechanisms and pathways are being continually discovered 47,71. As
such, BPA may affect StAR protein levels through an undiscovered novel mechanism.
However, there are a few possible mechanisms that may underlie BPA-induced StAR
protein levels, which include: (1) Changes in the 32-kDa isoform of StAR

72,73

, which I was

unable to detect by western blotting. The role of the 32-kDa isoform of StAR is not fully
understood, yet it is interesting to speculate that an increase in the mature 30-kDa StAR
may be complimented by a corresponding decrease in the 32-kDa StAR; (2) alterations in
transport and/or cleavage of StAR protein at the OMM. It was proposed that a change in
transport and/or cleavage of StAR would need to be accompanied with a change in StAR
pre-protein. However, this may not be the case and further investigation to confirm this is
needed; and (3) changes in multiple steps of the StAR regulation pathway. As such, if
there are changes in multiple steps of the StAR regulation pathway, smaller changes in
individual steps may not be sensitive enough to be detected in these experiments. Further
studies need to examine each of these potential mechanisms.

5.2.3

To determine whether aspects of the signaling pathway
identified in vitro can be observed in BPA-exposed mouse
adrenal glands

In Chapter 4, I presented a novel molecular pathway by which BPA acts on ERb to
activate the Shh signaling pathway, which in turn leads to increased cell proliferation in
H295A cells. However, future studies are necessary to determine whether this same
molecular pathway operates in vivo in the adrenal glands of both fetal and adult mouse
offspring following prenatal BPA exposure. These include (1) measuring key
proliferation markers and factors (PCNA, cyclin D1, and cyclin D2); (2) determining the
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levels (mRNA and protein) of key Shh signaling pathway factors Shh and Gli1, and their
activity in vivo (nuclear translocation of Gli1); and (3) examining levels of ERb and its
activity (nuclear translocation) in adrenal glands of both fetal and adult offspring after
prenatal BPA exposure. The foregoing experiments will ascertain whether the observed
mechanism in vitro is also in operation in vivo following prenatal exposure to BPA.

5.2.4

To determine the adrenal phenotype in ERa and ERb null
mice

It has previously been shown that estrogen is essential for adrenal gland development in
rhesus monkeys

36,42,74

. However, there are currently no known studies examining the

effects on adrenal gland development and/or function in ERa and ERb null mice.
Additionally, experiments in this thesis have demonstrated an important role of ER in
regulating adrenal steroidogenesis, as well as adrenal cortical cell proliferation via ERbmediated activation of the Shh signaling pathway. Thus, it is of important to characterize
adrenal gland phenotypes in both fetuses and adults of adrenal-specific ERa and ERb
knockout mice. These novel in vivo mouse models will define the role of ERa and ERb
during the development of the adrenal gland in the fetus, and the potential long-term
function of ERa and ERb in the adult offspring.
Generation of these mouse models would be useful in the future to further examine the
effects of BPA on adrenal gland development and function. Specifically, it will help to
further confirm the role of BPA in regulating adrenal steroidogenesis, and provide
definitive evidence to either support or refute if these effects are mediated through ERa
and/or ERb. These genetically modified mouse models will also be valuable in
confirming the role of ERb in activating the Shh signaling pathway, and consequent
stimulation of adrenal cortical cell proliferation. Additionally, these mouse models will
be invaluable in determining the mechanism of actions of other EDCs, acting through
ER, on adrenal gland development and function.
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5.2.5

To determine the effects of BPA analogues on adrenal gland
development and function

The continued research into the adverse effects of BPA has led to many manufacturers
discontinuing the use of BPA in their products

75,76

. As such, BPA analogues such as

Bisphenol S, F, and AF (BPS, BPF, and BPAF) are being used increasingly as
replacement for BPA in products due to their similar chemical properties (Figure 5.2)
75,76

. However, due to the structural similarities, there is potential for these chemicals to

not only exert the same effects as BPA but to cause other adverse effects. Indeed, recent
studies have found that exposure to BPS, BPF, and BPAF affect the reproductive

77,78

,

endocrine 77, neurological 79,80, cardiovascular 81, and metabolic 82,83 systems.
It has previously been demonstrated that treatment of the H295R cell line (adult adrenal
gland) with increasing concentrations of BPS, BPF, and BPAF resulted in various effects
on steroidogenic function differing from that of BPA 84. Therefore, future in vitro and in
vivo studies are needed to further understand the potential adverse effects of these
bisphenol analogues on adrenal development and function, which will contribute to the
growing literature concerning the question of whether bisphenol analogues are safer
alternatives to BPA.
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Figure 5.2: BPA and its analogues structure 84
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5.3

Conclusions

Insults during the critical period of development can often lead to long-term adverse
effects, resulting in disease and dysfunction in later life

13,14

. Exposure to EDCs such as

BPA during critical periods of organ development is alarming for numerous reasons.
First, the presence of BPA in the environment is ubiquitous, and is detectable in the urine
of over 91% of Canadians 85. Second, BPA has been demonstrated to cross the placenta
and reach fetal circulation during organ development 86,87. Lastly, BPA is known to work
through several receptors and alter numerous cell signaling pathways that are involved in
organ development

61,88

. While more attention has been placed on restricting/eliminating

the exposure of infants to BPA, specifically by banning BPA in baby bottles and
products, this does not prevent exposure of the fetus to BPA through maternal exposure
89,90

. Epidemiological and animal studies have demonstrated the potential for prenatal

BPA to cause HPA dysfunction 1-6. However, the specific effects of prenatal BPA on the
adrenal gland development and function in later life remain largely unknown.
The experiments presented in Chapter 2 demonstrates the effects of environmentally
relevant doses of prenatal BPA induces adrenal steroidogenesis independent of ACTH
levels in a sex-specific manner in the mouse model. The next set of experiments,
described in Chapter 3, present a potential mechanism by which BPA induces StAR
protein expression, the rate-limiting factor of steroidogenesis, seen in adult female mice
prenatally exposed to BPA. Lastly, experiments in Chapter 4 provided evidence of BPA
altering adrenal development by increasing adrenal cell proliferation via ERb-mediated
activation of the shh signaling pathway in human adrenocortical cells. A schematic of this
molecular pathway through which BPA induces adrenal cell proliferation is shown in
Figure 5.1. This model speculates that BPA freely crosses the cell membrane, which then
binds to and activates ERb, leading to ERb translocation to the nucleus and consequently
increasing Shh mRNA and protein levels. Shh is then secreted and acts in an
autocrine/paracrine fashion to bind to Ptch1 receptor, prevent Ptch1 from inhibiting
SMO. SMO is released from the plasma membrane into the cytoplasm, leading to the
release of a complex containing Gli1, a key Shh transcription factor. Gli1 translocates to
the nucleus where it binds to the promoters of key proliferation factors CCND1 and
CCND2, and enhances their transcription and ultimately leading to increased cell
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proliferation. This is a postulated model and further experiments are required to confirm
if this model translates into an in vivo model system. The long-term consequences of
increased cell proliferation in fetal adrenal glands must also be considered in the
application of this model.
Thus, this thesis supports the hypothesis that prenatal BPA exposure disrupts adrenal
gland development and steroidogenic function in adult offspring. These findings raise
concerns about the potential for adverse effects of prenatal BPA on adrenal gland
development and function, adding to the growing epidemiological evidence suggesting
adverse effects of BPA on the HPA axis and adrenal gland, and which we hope will
promote the continual banning of BPA in consumer products by regulatory agencies.

5.4
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